Document and Entity Information
Document and Entity Information - USD ($) $ in Billions | 12 Months Ended | ||
Dec. 31, 2022 | Feb. 27, 2023 | Jun. 30, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Fiscal Year Focus | 2022 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | CYTK | ||
Entity Registrant Name | CYTOKINETICS, INCORPORATED | ||
Entity Central Index Key | 0001061983 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Common Stock, Shares Outstanding | 95,161,391 | ||
Entity Public Float | $ 2 | ||
Entity Interactive Data Current | Yes | ||
Title of 12(b) Security | Common Stock, $0.001 par value | ||
Security Exchange Name | NASDAQ | ||
Entity File Number | 000-50633 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 94-3291317 | ||
Entity Address, Address Line One | 350 Oyster Point Boulevard | ||
Entity Address, City or Town | South San Francisco | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 94080 | ||
City Area Code | 650 | ||
Local Phone Number | 624-3000 | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
ICFR Auditor Attestation Flag | true | ||
Documents Incorporated by Reference | Portions of the Registrant’s Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission, no later than 120 days after the end of the fiscal year, are incorporated by reference into Part III of this Annual Report on Form 10-K. | ||
Auditor Name | Ernst & Young LLP | ||
Auditor Firm ID | 42 | ||
Auditor Location | San Mateo, California |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 65,582 | $ 112,666 |
Short-term investments | 716,995 | 358,972 |
Accounts receivable | 147 | 51,819 |
Prepaid expenses and other current assets | 12,462 | 12,215 |
Total current assets | 795,186 | 535,672 |
Long-term investments | 46,708 | 152,050 |
Property and equipment, net | 80,453 | 73,271 |
Operating lease right-of-use assets | 82,737 | 73,138 |
Other assets | 9,691 | 7,188 |
Total assets | 1,014,775 | 841,319 |
Current liabilities: | ||
Accounts payable | 25,611 | 21,087 |
Accrued liabilities | 44,096 | 34,370 |
Short-term operating lease liabilities | 12,829 | 14,863 |
Other current liabilities | 2,081 | 1,540 |
Total current liabilities | 84,617 | 71,860 |
Term loan, net | 63,810 | 47,367 |
Convertible notes, net | 545,808 | 95,471 |
Liabilities related to revenue participation right purchase agreements, net | 300,501 | 179,072 |
Long-term deferred revenue | 0 | 87,000 |
Long-term operating lease liabilities | 126,895 | 112,229 |
Other non-current liabilities | 1,044 | 4,457 |
Total liabilities | 1,122,675 | 597,456 |
Commitments and contingencies | ||
Stockholders' (deficit) equity: | ||
Preferred stock, $0.001 par value: Authorized: 10,000,000 shares; Issued and outstanding: none | 0 | 0 |
Common stock, $0.001 par value: Authorized: 163,000,000 shares; Issued and outstanding: 94,833,975 shares at December 31, 2022 and 84,799,542 shares at December 31, 2021 | 94 | 84 |
Additional paid-in capital | 1,481,590 | 1,452,268 |
Accumulated other comprehensive loss | (3,590) | (869) |
Accumulated deficit | (1,585,994) | (1,207,620) |
Total stockholders' (deficit) equity | (107,900) | 243,863 |
Total liabilities and stockholders' (deficit) equity | $ 1,014,775 | $ 841,319 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 163,000,000 | 163,000,000 |
Common stock, shares issued | 94,833,975 | 84,799,542 |
Common stock, shares outstanding | 94,833,975 | 84,799,542 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Total revenues | $ 94,588 | $ 70,428 | $ 55,828 |
Operating expenses: | |||
Research and development | 240,813 | 159,938 | 96,951 |
General and administrative | 177,977 | 96,803 | 52,820 |
Total operating expenses | 418,790 | 256,741 | 149,771 |
Operating loss | (324,202) | (186,313) | (93,943) |
Interest expense | (19,414) | (16,440) | (15,963) |
Loss on settlement of debt | (24,939) | 0 | 0 |
Non-cash interest expense on liabilities related to revenue participation right purchase agreements | (31,742) | (12,892) | (22,713) |
Interest and other income, net | 11,342 | 331 | 5,329 |
Net loss | $ (388,955) | $ (215,314) | $ (127,290) |
Net loss per share - basic | $ (4.33) | $ (2.80) | $ (1.97) |
Net loss per share - diluted | $ (4.33) | $ (2.80) | $ (1.97) |
Weighted-average number of shares used in computing net loss per share - basic | 89,825 | 76,886 | 64,524 |
Weighted-average number of shares used in computing net loss per share - diluted | 89,825 | 76,886 | 64,524 |
Other comprehensive loss: | |||
Unrealized loss on available-for-sale securities, net | $ (2,721) | $ (1,018) | $ (530) |
Comprehensive loss | (391,676) | (216,332) | (127,820) |
Research and Development Revenues [Member] | |||
Revenues: | |||
Total revenues | 6,588 | 10,572 | 16,527 |
License Revenues [Member] | |||
Revenues: | |||
Total revenues | 0 | 54,856 | 36,501 |
Milestone Revenues [Member] | |||
Revenues: | |||
Total revenues | 1,000 | 5,000 | 2,800 |
Realization of Revenue Participation Right Purchase Agreement [Member] | |||
Revenues: | |||
Total revenues | $ 87,000 | $ 0 | $ 0 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive (Loss) Income [Member] | Accumulated Deficit [Member] |
Beginning Balance at Dec. 31, 2019 | $ (10,937) | $ 59 | $ 853,341 | $ 679 | $ (865,016) |
Beginning Balance, shares at Dec. 31, 2019 | 59,172,124 | ||||
Exercise of stock options, value | 7,611 | $ 1 | 7,610 | 0 | 0 |
Exercise of stock options, shares | 943,505 | ||||
Exercise of warrants, value | 0 | $ 0 | 0 | 0 | 0 |
Exercise of warrants, share | 104,890 | ||||
Claims settlement under Section 16(b) | 2,151 | $ 0 | 2,151 | 0 | 0 |
Underwritten public offering of common stock, net of discounts, commissions and offering cost | 188,883 | $ 8 | 188,875 | 0 | 0 |
Underwritten public offering of common stock, net of discounts, commissions and offering cost, shares | 8,385,417 | ||||
Issuance of common stock upon private placement, value | 36,437 | $ 2 | 36,435 | 0 | 0 |
Issuance of common stock upon private placement, shares | 2,000,000 | ||||
Issuance under Employee Stock Purchase Plan, value | 1,509 | $ 0 | 1,509 | 0 | 0 |
Issuance under Employee Stock Purchase Plan, shares | 134,684 | ||||
Vesting of restricted stock units, net of taxes withheld, / Shares withheld related to net share settlement of equity awards value | (2,255) | $ 0 | (2,255) | 0 | 0 |
Vesting of restricted stock units, net of taxes withheld / Shares withheld related to net share settlement of equity awards, shares | 274,563 | ||||
Issuance of warrants | 184 | $ 0 | 184 | 0 | 0 |
Stock-based compensation | 17,620 | 0 | 17,620 | 0 | 0 |
Other comprehensive income (loss) | (530) | 0 | 0 | (530) | 0 |
Net loss | (127,290) | 0 | 0 | 0 | (127,290) |
Ending Balance at Dec. 31, 2020 | 113,383 | $ 70 | 1,105,470 | 149 | (992,306) |
Ending Balance, shares at Dec. 31, 2020 | 71,015,183 | ||||
Exercise of stock options, value | 11,020 | $ 3 | 11,017 | 0 | 0 |
Exercise of stock options, shares | 1,304,347 | ||||
Net share settlement | (418) | $ 0 | (418) | 0 | 0 |
Underwritten public offering of common stock, net of discounts, commissions and offering cost | 296,905 | $ 11 | 296,894 | 0 | 0 |
Underwritten public offering of common stock, net of discounts, commissions and offering cost, shares | 11,500,000 | ||||
Issuance of common stock upon private placement, value | 15,144 | 15,144 | 0 | 0 | |
Issuance of common stock upon private placement, shares | 511,182 | ||||
Issuance under Employee Stock Purchase Plan, value | 1,778 | $ 0 | 1,778 | 0 | 0 |
Issuance under Employee Stock Purchase Plan, shares | 108,780 | ||||
Vesting of restricted stock units, net of taxes withheld, / Shares withheld related to net share settlement of equity awards value | (4,449) | $ 0 | (4,449) | 0 | 0 |
Vesting of restricted stock units, net of taxes withheld / Shares withheld related to net share settlement of equity awards, shares | 360,050 | ||||
Stock-based compensation | 26,832 | $ 0 | 26,832 | 0 | 0 |
Other comprehensive income (loss) | (1,018) | 0 | 0 | (1,018) | 0 |
Net loss | (215,314) | 0 | 0 | 0 | (215,314) |
Ending Balance at Dec. 31, 2021 | 243,863 | 84 | 1,452,268 | (869) | (1,207,620) |
Ending Balance (ASU 2020-06 [Member]) at Dec. 31, 2021 | (38,895) | $ 0 | (49,476) | 0 | 10,581 |
Ending Balance, shares at Dec. 31, 2021 | 84,799,542 | ||||
Ending Balance, shares (ASU 2020-06 [Member]) at Dec. 31, 2021 | 0 | ||||
Exercise of stock options, value | 14,316 | $ 2 | 14,314 | 0 | 0 |
Exercise of stock options, shares | 1,389,031 | ||||
Exercise of warrants, value | 0 | $ 0 | 0 | 0 | 0 |
Exercise of warrants, share | 28,306 | ||||
Issuance of common stock under restricted stock units | 0 | $ 0 | 0 | 0 | 0 |
Issuance of common stock under restricted stock units, Shares | 707,772 | ||||
Issuance under Employee Stock Purchase Plan, value | 3,227 | $ 0 | 3,227 | 0 | 0 |
Issuance under Employee Stock Purchase Plan, shares | 98,153 | ||||
Vesting of restricted stock units, net of taxes withheld, / Shares withheld related to net share settlement of equity awards value | (9,602) | $ 0 | (9,602) | 0 | 0 |
Vesting of restricted stock units, net of taxes withheld / Shares withheld related to net share settlement of equity awards, shares | (260,172) | ||||
Induced conversion of convertible notes | (3,378) | $ 8 | (3,386) | 0 | 0 |
Induced conversion of convertible notes, shares | 8,071,343 | ||||
Settlement of capped call on 2026 Notes | 26,392 | $ 0 | 26,392 | 0 | 0 |
Stock-based compensation | 47,853 | 0 | 47,853 | 0 | 0 |
Other comprehensive income (loss) | (2,721) | 0 | 0 | (2,721) | 0 |
Net loss | (388,955) | 0 | 0 | 0 | (388,955) |
Ending Balance at Dec. 31, 2022 | $ (107,900) | $ 94 | $ 1,481,590 | $ (3,590) | $ (1,585,994) |
Ending Balance, shares at Dec. 31, 2022 | 94,833,975 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | |||
Net loss | $ (388,955) | $ (215,314) | $ (127,290) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||
Non-cash interest expense on liabilities related to revenue participation right purchase agreement | 31,858 | 13,004 | 22,792 |
Stock-based compensation expense | 47,853 | 26,832 | 17,620 |
Non-cash lease expense | 2,585 | 7,361 | 4,221 |
Impairment of right-of-use assets | 0 | 2,844 | 0 |
Depreciation of property and equipment | 5,814 | 2,276 | 1,831 |
Loss (gain) on investment, net | 107 | 0 | (573) |
Interest receivable and amortization on investments | (4,710) | 4,894 | (1,194) |
Non-cash interest expense related to debt | 5,697 | 7,125 | 6,640 |
Loss on extinguishment of debt | 2,693 | 0 | 0 |
Loss on inducement of convertible debt | 22,246 | 0 | 0 |
Changes in operating assets and liabilities: | |||
Accounts receivable | 56,672 | (47,399) | 743 |
Prepaid and other assets | (7,414) | (7,381) | (5,162) |
Accounts payable | 4,524 | 1,055 | (110) |
Accrued and other liabilities | 10,844 | 15,060 | 7,117 |
Deferred revenue | (87,000) | 0 | 87,000 |
Operating lease liabilities | 1,728 | 43,472 | (4,692) |
Other non-current liabilities | (4,058) | 3,649 | 0 |
Net cash (used in) provided by operating activities | (299,516) | (142,522) | 8,943 |
Cash flows from investing activities: | |||
Purchases of investments | (855,393) | (525,042) | (435,825) |
Maturities of investments | 604,594 | 422,837 | 247,301 |
Sales of investments | 0 | 3,300 | 3,061 |
Purchases of property and equipment | (11,335) | (48,872) | (11,052) |
Net cash used in investing activities | (262,134) | (147,777) | (196,515) |
Cash flows from financing activities: | |||
Repayment of finance lease liabilities | (944) | 0 | 0 |
Repayment of term loan | (47,651) | 0 | 0 |
Debt extinguishment costs | (2,409) | 0 | 0 |
Repayment of convertible debt | (140,330) | 0 | 0 |
Proceeds from issuance of convertible debt, net | 523,586 | 0 | 0 |
Proceeds from public offerings of common stock, net of discounts, commissions and offering cost | 0 | 296,905 | 188,883 |
Proceeds from private placement, net | 0 | 15,144 | 36,225 |
Proceeds from 2022 RPI Transactions, net | 149,581 | 0 | 0 |
Proceeds from issuance of common stock under equity incentive and stock purchase plans | 17,543 | 12,380 | 9,120 |
Taxes paid related to net share settlement of equity awards | (9,602) | (4,449) | (2,255) |
Claims settlement under Section 16(b) | 0 | 0 | 2,151 |
Cash Settlement of capped call options associated with 2026 Notes | 26,392 | 0 | 0 |
Net cash provided by financing activities | 516,166 | 319,980 | 234,124 |
Net (decrease) increase in cash, cash equivalents, and restricted cash equivalents | (45,484) | 29,681 | 46,552 |
Cash, cash equivalents, and restricted cash equivalents, beginning of period | 112,666 | 82,985 | 36,433 |
Cash, cash equivalents, and restricted cash equivalents, end of period | 67,182 | 112,666 | 82,985 |
Supplemental cash flow disclosures: | |||
Cash paid for interest | 15,165 | 9,175 | 9,620 |
Right-of-use assets recognized in exchange for operating lease obligations | 10,904 | 80,395 | 1,106 |
Right-of-use assets recognized in exchange for finance lease obligations | 1,055 | 1,294 | 0 |
Amounts unpaid for purchases of property and equipment | 621 | 11,982 | 0 |
Issuance of common stock in connection with repurchase of convertible note | $ 317,123 | $ 0 | $ 0 |
Organization and Accounting Pol
Organization and Accounting Policies | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Accounting Policies | Note 1 — Organization and Accounting Policies Organization Cytokinetics, Incorporated (the “Company”, “we” or “our”) was incorporated under the laws of the state of Delaware on August 5, 1997. We are a late-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Our financial statements contemplate the conduct of our operations in the normal course of business. We have incurred an accumulated deficit of approximately $ 1.6 billion since inception and there can be no assurance that we will attain profitability. We had a net loss of $ 389.0 million and net cash used in operations of $ 299.5 million for the year ended December 31, 2022. Cash, cash equivalents, and investments increased to $ 829.3 million as of December 31, 2022 from $ 623.7 million as of December 31, 2021. We anticipate that we will have operating losses and net cash outflows in future periods. We are subject to risks common to late-stage biopharmaceutical companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund our future plans. Our liquidity will be impaired if sufficient additional capital is not available on terms acceptable to us. To date, we have funded operations primarily through sales of our common stock, contract payments under our collaboration agreements, sales of future revenues and royalties, debt financing arrangements, government grants and interest income. Until we achieve profitable operations, we intend to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. We have never generated revenues from commercial sales of our drugs and may not have drugs to market for at least several years, if ever. Our success is dependent on our ability to enter into new strategic collaborations and/or raise additional capital and to successfully develop and market one or more of our drug candidates. We cannot be certain that sufficient funds will be available from such a financing or through a collaborator when required or on satisfactory terms. Additionally, there can be no assurance that our drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on our future financial results, financial position and cash flows. Based on the current status of our research and development activities, we believe that our existing cash, cash equivalents, and investments will be sufficient to fund cash requirements for at least the next 12 months after the issuance of these consolidated financial statements. If, at any time, our prospects for financing our research and development programs decline, we may decide to reduce research and development expenses by delaying, discontinuing or reducing our funding of one or more of our research or development programs. Alternatively, we might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements do not include any adjustments that might result from the outcome of this uncertainty . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an ongoing basis. We base our estimates on our historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates. Basis of Presentation The consolidated financial statements include the accounts of Cytokinetics, Incorporated and its wholly-owned subsidiaries and have been prepared in accordance with GAAP. Intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform the prior period presentation to the current year. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of risk consist principally of cash, cash equivalents, restricted cash equivalents, investments, and accounts receivable. Our cash, cash equivalents, restricted cash equivalents, and investments held with large financial institutions in the United States and deposits may exceed the Federal Deposit Insurance Corporation’s insurance limit. Our exposure to credit risk associated with non-payment includes, but is not limited to, Astellas Pharma Inc. for co-funding one-third of the out-of-pocket clinical development costs which may be incurred in connection with Cytokinetics’ Phase 3 clinical trial, COURAGE-ALS, of reldesemtiv in ALS up to a maximum contribution by Astellas of $ 12.0 million, to our strategic partner in China and Taiwan, Ji Xing , and RPI ICAV, to whom we sold a revenue interest in our net sales of pharmaceutical products containing aficamten under the RP Aficamten RPA, as further described in Note 11 below. Drug candidates we develop may require approvals or clearances from the FDA or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us. Cash, Cash Equivalents, and Restricted Cash Equivalents We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents, which consist of money market funds and repurchase agreements backed by U.S. Treasury securities. Repurchase agreements are collateralized by US Treasury securities for an amount not less than 102 % of their value and are reported at a carrying value which approximates fair value due to their short duration. A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in our consolidated balance sheets to the amount reported within our consolidated statements of cash flows was as follows (in thousand): December 31, 2022 2021 Cash and cash equivalents $ 65,582 $ 112,666 Restricted cash equivalents 1,600 — Total cash, cash equivalents, and restricted cash equivalents as reported within our consolidated statement of cash flows $ 67,182 $ 112,666 As of December 31, 2022 , our restricted cash equivalents balance of $ 1.6 million is used to collateralize the letters of credit associated with our fixed and variable rate vehicle allowance and short-term car rental programs. The restricted cash equivalents are classified as other assets based on the remaining term of the underlying restriction. The letters of credit will lapse at the end of the respective contractual terms or upon termination of the arrangement. Investments Available-for-sale investments. Our investments consist of U.S. Treasury securities, U.S. and non-U.S. government agency bonds, commercial paper, global portfolio of corporate debt and money market funds. We designate all investments as available-for-sale and report them at fair value, based on quoted market prices, with unrealized gains and losses recorded in accumulated other comprehensive loss. The cost of securities sold is based on the specific-identification method. Investments with original maturities greater than three months and remaining maturities of one year or less are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. All of our available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, we determine if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors. If the impairment is a result of a credit-related loss, we recognize an allowance for credit losses. If the impairment is not a result of a credit loss, we recognize the loss in other comprehensive loss. Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three years for computer equipment and software, five years for laboratory equipment and office equipment, and seven years for furniture and fixtures. Amortization of leasehold improvements and finance lease right-of-use assets are computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, typically ranging from three to twenty-two years . Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Impairment of Long-lived Assets We review long-lived assets, including property, equipment and right-of-use assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Impairment is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. We would recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Leases We determine if the arrangement contains a lease at inception based on whether the contract conveys the right to control the use of an identified asset. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company, and preliminary based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease). We determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. In addition to the fixed minimum lease payments required under the lease arrangements, certain leases include payments of operating expenses that may be revised based on the landlord’s estimate. These variable payments are excluded from the lease payments used to determine the right-of-use asset and lease liability and are recognized when the associated activity occurs. We recognize right-of-use assets and short-term and long-term lease liabilities on our consolidated balance sheets for operating leases. The right-of-use asset and short-term and long-term lease liabilities for finance leases are recognized in property and equipment, other current liabilities, and other non-current liabilities, respectively, on the consolidated balance sheets. In determining the present value of lease payments, we estimated our incremental borrowing rate based on information available upon commencement. We base the lease liabilities on the present value of remaining lease payments over the remaining terms of the leases using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The initial right-of-use asset, for both operating and finance leases, is measured based on the lease liability adjusted for any initial direct costs, lease prepayments, and lease incentives. We recognize rent expense for operating leases on a straight-line basis over the lease term in operating expenses on the consolidated statements of operations. Finance lease right-of-use assets are amortized on a straight-line basis over the shorter of the expected useful life or the lease term, and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded in interest expense. We exclude from our consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases). We account for lease and non-lease components as a single component for our operating leases. Our operating leases consist of the facilities leases with KR Oyster Point 1, LLC and a facility located in Radnor, Pennsylvania, and our finance leases are for laboratory equipment. Revenue Recognition We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration for those goods or services. To recognize revenue from a contract with a customer, we: (i) identify our contracts with our customers; (ii) identify our distinct performance obligations in each contract; (iii) determine the transaction price of each contract; (iv) allocate the transaction price to the performance obligations; and (v) recognize revenue as we satisfy our performance obligations. At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Collaborative Arrangements We enter into collaborative arrangements with partners that typically include payment to us for one of more of the following: (i) license fees; (ii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; and (iv) research and development cost reimbursements. Each of these payments results in collaboration or other revenues. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied. As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The stand-alone selling price may include such items as, forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, to determine the transaction price to allocate to each performance obligation. For our collaboration agreements that include more than one performance obligation, such as a license and/or milestones combined with a commitment to perform research and development services, we make judgments to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate our progress each reporting period and, if necessary, adjust the measure of a performance obligation and related revenue recognition. License Fees : If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Milestone Payments : We use judgment to determine whether a milestone is considered probable of being reached. Using the most likely amount method, we include the value of a milestone payment in the consideration for a contract at inception if we then conclude achieving the milestone is more likely than not. Otherwise, we exclude the value of a milestone payment from contract consideration at inception and recognize revenue for a milestone at a later date, when we judge that it is probable the milestone will be achieved. If we conclude it is probable that a significant revenue reversal would not occur, the associated milestone is included in the transaction price. We then allocate the transaction price to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Royalties : For contracts that include sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. To date, we have not recognized any royalty revenues resulting from contracts. Research and Development Cost Reimbursements : Our joint programs with Astellas under the Astellas OSSA Agreement, and with Amgen under the Amgen Agreement (both of the Astellas OSSA Agreement and the Amgen Agreement having now been terminated), included promises of research and development services. We also entered into the Astellas FSRA Agreement on April 23, 2020. Under the Astellas FSRA Agreement, As tellas agreed to pay one-third of the out-of-pocket clinical development costs which may be incurred in connection with the Company’s Phase 3 clinical trial of reldesemtiv in ALS, up to a maximum contribution by Astellas of $ 12.0 million. We determined that these services collectively were distinct from any licenses provided to Astellas and Amgen under such agreements, and as such, these services were accounted for as a separate performance obligation recorded over time. We recognized revenue for these services as the performance obligations are satisfied, which we estimated using internal research and development costs incurred. Accrued Research and Development Expenditures Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Revenue Participation Right Purchase Agreements We have entered into certain revenue participation right purchase agreements with certain investors, pursuant to which such investors purchased rights to royalties from certain revenue streams in exchange for consideration. We typically account for such agreements as debt to be amortized under the effective interest rate method over the life of the related royalty stream, when we have continuing involvement with the underlying R&D. We typically account for such agreements as deferred income to be amortized under the units-of-revenue method, when there is no continuing involvement with the underlying R&D. Revenue participation right purchase agreements are recognized using significant unobservable inputs. These inputs are derived using internal management estimates developed based on third party data and reflect management’s judgements, current market conditions surrounding competing products, and forecasts. We will periodically assess the amount and timing of expected royalty payments and account for any changes in such estimates on a prospective basis . Research and Development Expenditures Research and development costs are charged to operations as incurred. Research and development expenses consist primarily of clinical manufacturing costs, preclinical study expenses, consulting and other third-party costs, employee compensation, supplies and materials, allocation of overhead and occupancy costs, facilities costs and depreciation of equipment. Income Taxes We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. We recognize uncertain tax positions taken or expected to be taken on a tax return. Tax positions are initially recognized when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is more likely than not of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. We recognize interest accrued related to unrecognized tax benefits and penalties as income tax expense. Stock-Based Compensation We maintain equity incentive plans under which incentive stock options may be granted to employees and nonqualified stock options, restricted stock awards, performance-based stock units and stock appreciation rights may be granted to employees, directors, consultants and advisors. In addition, we maintain an ESPP under which employees may purchase shares of our common stock through payroll deductions. Stock-based compensation expense related to stock options granted to employees and directors is recognized based on the grant date estimated fair values using the Black Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. Stock-based compensation expense related to performance-based stock units granted to employees is recognized based on the grant-date fair value of each award and recorded as expense over the vesting period using the ratable method when the underlying performance conditions are deemed probable. Stock-based compensation expense related to the ESPP is recognized based on the fair value of each award estimated on the first day of the offering period using the Black Scholes option pricing model and recorded as expense over the service period using the straight-line method. Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06. Under ASU 2020-06 the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument is accounted for as a single liability measured at its amortized cost and convertible preferred stock is accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. We adopted this new guidance using the modified retrospective method as of January 1, 2022, with respect to our 2026 Notes. The cumulative effect of initially applying the new standard was recognized as an adjustment to accumulated deficit. The following table summarizes the adjustments made to our consolidated balance sheet as of January 1, 2022, upon adoption of the new standard (in 000's): Balance sheet account description Ending Balance ASU 2020-06 Adjustments Beginning Balance Convertible notes, net $ 95,471 $ 38,895 $ 134,366 Additional paid-in capital 1,452,268 ( 49,476 ) 1,402,792 Accumulated deficit ( 1,207,620 ) 10,581 ( 1,197,039 ) The adoption of this new guidance resulted in an increase in the carrying value of the 2026 Notes to reflect the full principal amount of the convertible notes outstanding, net of issuance costs, a decrease in additional paid-in capital to remove the equity component separately recorded for the conversion feature associated with the convertible notes, a cumulative-effect adjustment to the beginning balance of our accumulated deficit as of January 1, 2022 to reverse the accretion of discount that resulted from the bifurcation of the equity component of the 2026 Notes, and a reversal of the related deferred tax liability of $ 8.3 million with a corresponding increase in our deferred tax asset valuation allowance. The adoption of this new guidance reduced non-cash interest expense for the year ending December 31, 2022 and will continue to do so until the 2026 Notes have been settled. The remaining debt issuance costs will continue to be amortized over the term of the notes. We have recognized $ 3.6 million of interest expense of the 2026 Notes in 2022 which is $ 3.3 million less than under the previous accounting standards in 2022. Without the adoption of ASU 2020-06, our reported net loss would have increased by $ 3.3 million in 2022. Without the adoption of ASU 2020-06, our reported net loss per share would have increased by $ 0.04 per share in 2022. On July 6, 2022, the Company issued the 2027 Notes and partially repurchased the 2026 Notes as further described in Note 7 – “Debt.” ASU 2020-06 was applied to the 2027 Notes from the moment of issuance, and thus the above adjustments apply only to the 2026 Notes. |
Net Loss Per Share
Net Loss Per Share | 12 Months Ended |
Dec. 31, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | Note 2 — Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net loss per share is computed by giving effect to all potentially dilutive common shares, including outstanding stock options, unvested restricted stock, warrants, convertible preferred stock and shares issuable under our ESPP, during the period using the treasury stock method and convertible notes using the if-converted method. The following instruments were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been antidilutive (in thousands): Years Ended December 31, 2022 2021 2020 Options to purchase common stock 10,992 9,373 8,510 Warrants to purchase common stock 13 48 48 Restricted stock and performance units 1,260 1,415 1,117 Shares issuable related to the ESPP 13 8 12 Shares issuable upon conversion of 2026 Notes 2,554 16,675 16,675 Shares issuable upon conversion of 2027 Notes 10,572 — — Total shares 25,404 27,519 26,362 |
Research and Development Arrang
Research and Development Arrangements | 12 Months Ended |
Dec. 31, 2022 | |
Research and Development [Abstract] | |
Research and Development Arrangements | Note 3 — Research and Development Arrangements 2021 Ji Xing and RTW Transactions In December 2021, we entered into the 2021 RTW Transactions with parties that were at the time of our entry into the 2021 RTW Transactions affiliated and in contemplation of one another and, accordingly, we have assessed the accounting for these transactions in the aggregate. Unconstrained arrangement consideration under the 2021 RTW Transactions totaled $70.0 million and was allocated in accordance with ASC 820, Fair Value Measurement, and ASC 606, Revenue from Contracts with Customers, as follows (in thousands): Allocated Units of Accounting: License and collaboration $ 54,856 Common stock (fair value) 15,144 Total consideration $ 70,000 Ji Xing Omecamtiv Mecarbil License and Collaboration Agreement On December 20, 2021, we entered into the Ji Xing OM License Agreement, pursuant to which we granted to Ji Xing an exclusive license to develop and commercialize omecamtiv mecarbil in China and Taiwan. Under the terms of the Ji Xing OM License Agreement, we are the beneficiary of a nonrefundable $ 50.0 million payment obligation from Ji Xing comprised of a $ 40.0 million payment as consideration for the rights granted by us to Ji Xing and $ 10.0 million attributable to our having submitted to the FDA an NDA for omecamtiv mecarbil. The $ 50.0 million payment was received by the Company in January 2022. We may be eligible to receive from Ji Xing additional payments totaling up to $ 330.0 million for the achievement of certain commercial milestone events in connection to omecamtiv mecarbil. In addition, Ji Xing will pay us tiered royalties in the mid-teens to the low twenties range on the net sales of pharmaceutical products containing omecamtiv mecarbil in China and Taiwan, subject to certain reductions for generic competition, patent expiration and payments for licenses to third party patents. Ji Xing will be responsible for the development and commercialization of omecamtiv mecarbil at its own cost and is required to use diligent efforts to develop and commercialize omecamtiv mecarbil in China and Taiwan. The development of omecamtiv mecarbil will be initially focused on HFrEF, and Ji Xing will have the opportunity to participate in Cytokinetics’ global clinical trials of omecamtiv mecarbil. Cytokinetics will supply omecamtiv mecarbil to Ji Xing either as a finished product or as an active pharmaceutical ingredient. Ji Xing may reimburse Cytokinetics for certain costs related to development and supply activities that we performed on their behalf. The Ji Xing OM License Agreement, unless terminated earlier, will continue on a market-by-market basis until expiration of the relevant royalty term. Ji Xing has the right to terminate the Ji Xing OM License Agreement for convenience. Each party may terminate the Ji Xing OM License Agreement for the other party’s uncured material breach, insolvency, or failure to perform due to extended force majeure events. Cytokinetics may also terminate the Ji Xing OM License Agreement if Ji Xing challenges Cytokinetics’ patents or undergoes certain change of control transactions. Rights granted to Ji Xing in relation to omecamtiv mecarbil will revert to Cytokinetics upon termination, and, under certain circumstances, subject to a low single digit royalty payment by the Company to Ji Xing on the net sales of the products containing the compound omecamtiv mecarbil in China and Taiwan. We assessed this arrangement in accordance with ASC 606 and concluded that there is one performance obligation relating to the license of functional intellectual property. The performance obligation was satisfied, and we recognized the residual allocation of arrangement consideration as revenue of $ 54.9 million for 2021. Due to the nature of development, including the inherent risk of development and approval by regulatory authorities, we are unable to estimate if and when the development milestone payments could be achieved or become due and, accordingly, we consider the milestone payments to be fully constrained and excluded any potential milestone payments from the initial transaction price. The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur under the sales- and usage-based royalty exception as these amounts have been determined to relate predominantly to the license. We re-evaluate the probability of achievement of development milestones and any related constraints each reporting period. We will include consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Common Stock Purchase Agreements On December 20, 2021, as part of the 2021 RTW Transactions, we entered into common stock purchase agreements with each of the RTW Investors. These common stock purchase agreements provided for the sale and issuance of an aggregate of 511,182 shares of our common stock at a price per share of $ 39.125 and an aggregate purchase price of $ 20.0 million. The closing occurred on December 20, 2021 . The RTW Investors have agreed to certain trading and other restrictions with respect to the shares of common stock they purchased pursuant to these agreements, including a restriction on sales or other transfers of the shares, subject to certain exceptions, for a period of one year from the closing date. The restrictions resulted in a premium paid by the RTW Investors of $ 4.9 million, which represents the excess amount paid over the fair value of the shares of common stock purchased. The premium was determined by analyzing the restrictions discount applied to the closing stock price as of December 20, 2021, which is a Level 2 fair value input. The cash received less the calculated premium is the $ 15.1 million fair value of the common stock recorded . 2020 Ji Xing and RTW Transactions On July 14, 2020, we entered in the 2020 RTW Transactions, as described below, with RTW Royalty Holdings and Ji Xing , related to aficamten, our proprietary small molecule cardiac myosin inhibitor product, a novel cardiac myosin inhibitor, and other assets. The 2020 RTW Transactions include entering into a licensing and collaboration agreement with Ji Xing, the sale of Cytokinetics common stock to the RTW Investors, an agreement to sell to RTW Royalty Holdings our interest in certain future royalties on net sales of products containing the compound mavacamten that are or may be developed or commercialized by Bristol-Myers Squibb Company (formerly by MyoKardia, Inc.), including CAMZYOS tm (mavacamten), and the ability for the Company to obtain additional funding in the future from RTW Royalty Holdings, upon the achievement of certain clinical trial milestones, in exchange for future royalty payments as further discussed below. As a result, we have received and expect to receive a combination of license fees, milestone revenues and sale proceeds from the RTW Investors, RTW Royalty Holdings and Ji Xing. The 2020 RTW Transactions were entered into with parties that were at the time of our entry into the 2020 RTW Transactions affiliated and in contemplation of one another and, accordingly, we have assessed the accounting for these transactions in the aggregate. We concluded that there were three units of accounting in the 2020 RTW Transactions as further described below. The Company allocated the total consideration in accordance with ASC 820 and ASC 606 as follows (in thousands): Allocated Units of Accounting: License and collaboration (residual) $ 36,501 Royalty (fair value) 87,000 Common stock (fair value) 36,499 Total consideration $ 160,000 Ji Xing Aficamten License and Collaboration Agreement On July 14, 2020, we entered into the Ji Xing Aficamten License Agreement with Ji Xing, pursuant to which we granted to Ji Xing an exclusive license to develop and commercialize aficamten in China and Taiwan. Under the terms of the Ji Xing Aficamten License Agreement, we received from Ji Xing a nonrefundable upfront payment of $ 25.0 million. We may be eligible to receive from Ji Xing milestone payments totaling up to $ 200.0 million for the achievement of certain development and commercial milestone events in connection to aficamten in the field of oHCM and/or nHCM and other indications. In addition, Ji Xing will pay us tiered royalties in the low-to-high teens range on the net sales of the products containing aficamten in China and Taiwan, subject to certain reductions for generic competition, patent expiration and payments for licenses to third party patents. Ji Xing will be responsible for the development and commercialization of aficamten at its own cost and is required to use diligent efforts to develop and commercialize aficamten in China and Taiwan. The development of aficamten will be initially focused on HCM, and Ji Xing will have the opportunity to participate in Cytokinetics’ global pivotal clinical trials of aficamten. Cytokinetics or a designated supplier will supply aficamten to Ji Xing either as a finished product or as an active pharmaceutical ingredient. The Ji Xing Aficamten License Agreement, unless terminated earlier, will continue on a market-by-market basis until expiration of the relevant royalty term. Ji Xing has the right to terminate the Ji Xing Aficamten License Agreement for convenience. Each party may terminate the Ji Xing Aficamten License Agreement for the other party’s uncured material breach, insolvency, or failure to perform due to extended force majeure events. Cytokinetics may also terminate the Ji Xing Aficamten License Agreement if Ji Xing challenges Cytokinetics’ patents or undergoes certain change of control transactions. Rights granted to Ji Xing in relation to aficamten will revert to Cytokinetics upon termination, and, under certain circumstances, subject to a low single digit royalty payment by the Company to Ji Xing on the net sales of the products containing the compound aficamten in China and Taiwan. We assessed this arrangement in accordance with ASC 606 and concluded that there is one performance obligation relating to the license of functional intellectual property. The performance obligation was satisfied, and we recognized the residual allocation of arrangement consideration as revenue of $ 36.5 million for 2020. No license revenue was recognized in 2021 related to the Ji Xing Aficamten License Agreement. Due to the nature of development, including the inherent risk of development and approval by regulatory authorities, we are unable to estimate if and when the development milestone payments could be achieved or become due and, accordingly, we consider the milestone payments to be fully constrained and exclude the milestone payments from the initial transaction price. The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur under the sales and usage-based royalty exception of ASC 606 as these amounts have been determined to relate predominantly to the license. We re-evaluate the probability of achievement of development milestones and any related constraints each reporting period. We will include consideration, without constraint, in the transaction price to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We recognized a $ 5.0 million milestone from Ji Xing during the third quarter of 2021 for initiation of a phase 3 clinical trial for aficamten in oHCM. Although our contractual right to payment had not arisen under the Ji Xing Aficamten License Agreement, we determined recognition of the milestone in accordance with ASC 606 during the third quarter of 2021 was appropriate based on our expected initiation of a phase 3 clinical trial of aficamten in oHCM and was recorded as a corresponding contract asset in other current assets in our consolidated balance sheet as of December 31, 2021. Royalty Purchase Agreement On July 14, 2020, we entered the RTW Royalty Purchase Agreement with RTW Royalty Holdings, pursuant to which we sold our Mavacamten Royalty, under the Research Collaboration Agreement, dated August 24, 2012, between us and MyoKardia, Inc. to RTW Royalty Holdings for a one-time payment of $ 85.0 million. The RTW Royalty Purchase Agreement transaction closed on November 13, 2020. On March 31, 2021, RTW Royalty Holdings assigned its rights and obligations under the RTW Royalty Purchase Agreement to its affiliate, RTW ICAV. We understand that on April 18, 2022, RTW ICAV and MyoKardia, Inc. entered into agreements, which purported to assign all of RTW ICAV's rights, title and interest to the Mavacamten Royalty to MyoKardia, Inc., and on April 25, 2022, we entered into a tripartite agreement with RTW ICAV and MyoKardia, Inc. acknowledging the release and discharge of any further obligations by us or MyoKardia, Inc. in connection to the Mavacamten Royalty. The allocation of the consideration for the 2020 RTW Transactions resulted in $ 87.0 million being allocated to the RTW Royalty Purchase Agreement representing its fair value. The fair value was determined using an income approach method based on management’s estimates of the discounted cash flows to be received over the term of the related royalty agreement, which are Level 3 fair value inputs. Management’s estimates included significant unobservable inputs. These inputs are derived using internal management estimates developed based on third party data and reflect management’s judgements, current market conditions surrounding competing products, and forecasts. The significant unobservable inputs include the estimated patient population, estimated selling price, estimated peak sales and sales ramp, the expected term of the royalty stream, and timing of the expected launch. The $ 87.0 million was initially recorded as deferred revenue. On April 25, 2022, as discussed above, we entered into a tripartite agreement with RTW ICAV and MyoKardia, Inc. acknowledging the release and discharge of any further obligations by us or MyoKardia, Inc. in connection to the Mavacamten Royalty. As a result of the full extinguishment of the Mavacamten Royalty, we recognized revenue of $ 87.0 million. Common Stock Purchase Agreements On July 14, 2020, we entered into common stock purchase agreements with each of the RTW Investors. These common stock purchase agreements provided for the sale and issuance of an aggregate of 2.0 million shares of common stock of Cytokinetics at a price per share of $ 25.00 and an aggregate purchase price of $ 50.0 million. The closing occurred on July 14, 2020. The RTW Investors have agreed to certain trading and other restrictions with respect to the shares of common stock they purchased pursuant to these agreements, including a restriction on sales or other transfers of the shares, subject to certain exceptions, for a period of two years from the closing date, which period will be extended if certain conditions are met. The restrictions resulted in a premium paid by RTW investors of $ 13.5 million which represents the excess amount paid over the fair value of the shares of common stock purchased. The premium was determined by analyzing the holding period discount applied to the 30-day average stock price as of July 14, 2020 , which is a Level 2 fair value input. The cash received less the calculated premium is the $ 36.5 million fair value of the common stock recorded . Funding Agreement During July 2020, we also entered into a Funding Agreement (the “Funding Agreement”) with RTW Royalty Holdings. Pursuant to the Funding Agreement, RTW Royalty Holdings had committed to provide up to $ 90.0 million to fund our development and commercialization of aficamten in nHCM and oHCM. On January 7, 2022, we announced that we h ad elected to unilaterally terminate the Funding Agreement in connection with our entry into the RP Aficamten RPA (as defined below). At the time of its termination, we had not exercised any rights to sell any revenue interest in aficamten under the Funding Agreement. Astellas Our strategic alliance with Astellas to advance novel therapies for diseases and medical conditions associated with skeletal muscle impairment and weakness commenced in 2013 under the Astellas Agreement. On April 23, 2020, we and Astellas entered into the two agreements referenced below which, taken together, amend and restate the Company’s research, development and commercialization collaboration with Astellas under the Astellas Agreement. Fast Skeletal Regulatory Activator Agreement The Company and Astellas entered into the Astellas FSRA Agreement on April 23, 2020. As a result of the Astellas FSRA Agreement, the Company will now have exclusive control and responsibility for the Company's future development and commercialization of reldesemtiv, CK-601 and other FSRA compounds and products, and accordingly, Astellas has agreed to terminate its license to all FSRA compounds and related products. Under the Astellas FSRA Agreement, Astellas agreed to pay one-third of the out-of-pocket clinical development costs which may be incurred in connection with the Company’s Phase 3 clinical trial of reldesemtiv in ALS, up to a maximum contribution by Astellas of $ 12 million. As of December 31, 2022, Astellas has reimbursed us $ 9.3 million. In addition, Astellas agreed to non-cash contributions to the Company, which include the transfer of its existing inventories of active pharmaceutical ingredient of reldesemtiv and CK-601. Astellas has also agreed to the continued conduct of ongoing stability studies pertaining to such existing inventories of active pharmaceutical ingredient, at Astellas’ cost. In exchange, the Company will pay Astellas a low- to mid- single digit royalty on sales of reldesemtiv in the United States, Canada, United Kingdom and the E.U. until the later of (i) ten years following the first commercial sale of such product in a major market country, or (ii) December 31, 2034, subject to certain royalty reduction provisions. The Company will not owe Astellas royalties on sales of reldesemtiv in any other country, or on the sale of any FSRA compounds or related products other than reldesemtiv. License and Collaboration Agreement for Other Skeletal Sarcomere Activators The Company and Astellas also entered into the Astellas OSSA Agreement, which is an amendment and restatement of the Astellas Agreement and removes the FSRA compounds and related products from the collaboration. On April 27, 2021, we received written notice of termination from Astellas of the Astellas OSSA Agreement. The termination of the Astellas OSSA Agreement was effective November 1, 2021. We recognized research revenue for reimbursements from Astellas of internal costs of certain full-time employee equivalents, supporting collaborative research and development programs, and of other costs related to those programs through March 31, 2021 when the research term of the Astellas OSSA Agreement expired. Research and development revenue from Astellas for 2022, 2021, and 2020 was $ 5.7 million , $ 3.2 million , and $ 6.6 million , respectively. We had no accounts receivable from Astellas as of December 31, 2022. We had accounts receivable from Astellas of $ 1.8 million as of December 31, 2021. Amgen On November 23, 2020, we received written notice of termination from Amgen of the Amgen Agreement pertaining to the discovery, development and commercialization of novel small molecule therapeutics, including omecamtiv mecarbil, a novel cardiac myosin activator, and CK-136 (formerly AMG 594), a novel cardiac troponin activator. The termination of the Amgen Agreement was effective May 20, 2021. We recognized research and development revenue for reimbursements from Amgen of both internal costs of certain full-time employee equivalents and other costs related to the Amgen Agreement, which terminated effective May 20, 2021. There was no research and development revenue from Amgen in 2022. Research and development revenue from Amgen was $ 7.4 million in 2021 and $ 10.0 million in 2020 and consists of reimbursement of costs we incurred related to METEORIC-HF. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 4 — Fair Value Measurements We value our financial assets and liabilities at fair value, defined as the price that would be received for assets when sold or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We utilize market data or assumptions that we believe market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable. We primarily apply the market approach for recurring fair value measurements and endeavor to utilize the best information reasonably available. Accordingly, we use valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider the security issuers’ and the third-party issuers’ credit risk in our assessment of fair value. We classify fair value based on the observability of those inputs using a hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement): Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities; Level 2 — Inputs, other than the quoted prices in active markets, that are observable either directly or through corroboration with observable market data; and Level 3 — Unobservable inputs, for which there is little or no market data for the assets or liabilities, such as internally-developed valuation models. Fair Value of Financial Assets The follow tables set forth the fair value of our financial assets, which consist of cash equivalents and investments classified as available-for-sale securities, that were measured on a recurring basis (in thousands) : December 31, 2022 Fair Value Hierarchy Level Amortized Unrealized Unrealized Fair Money market funds Level 1 $ 45,887 $ — $ — $ 45,887 U.S. Treasury securities Level 1 172,568 — ( 1,102 ) 171,466 U.S. Treasury securities backed repurchase agreements Level 2 16,003 — — 16,003 U.S. and non-U.S. government agency bonds Level 2 136,773 12 ( 889 ) 135,896 Commercial paper Level 2 329,359 28 ( 431 ) 328,956 U.S. and non-U.S. corporate obligations Level 2 128,594 — ( 1,209 ) 127,385 $ 829,184 $ 40 $ ( 3,631 ) $ 825,593 December 31, 2021 Fair Value Hierarchy Level Amortized Unrealized Unrealized Fair Money market funds Level 1 $ 115,937 $ — $ — $ 115,937 U.S. Treasury securities Level 1 133,498 1 ( 268 ) 133,231 U.S. government agency bonds Level 2 33,489 — ( 53 ) 33,436 Commercial paper Level 2 169,622 6 ( 19 ) 169,609 U.S. and non-U.S. corporate obligations Level 2 175,282 — ( 536 ) 174,746 $ 627,828 $ 7 $ ( 876 ) $ 626,959 The available-for-sale securities in our consolidated balance sheet are as follows (in thousands): December 31, 2022 December 31, 2021 Cash equivalents $ 61,890 $ 115,937 Short-term investments 716,995 358,972 Long-term investments 46,708 152,050 $ 825,593 $ 626,959 Interest income was $ 11.4 million , $ 1.0 million , and $ 5.3 million in 2022, 2021, and 2020, respectively. No credit losses on debt securities were recognized in either 2022 or 2021. In its evaluation to determine expected credit losses, management considered all available historical and current information, expectations of future economic conditions, the type of security, the credit rating of the security, and the size of the loss position, as well as other relevant information. The Company does not intend to sell, and is unlikely to be required to sell, any of these available-for-sale investments before their effective maturity or market price recovery. The carrying amount of our accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. There were no transfers between Level 1, Level 2, and Level 3 during the periods presented . |
Balance Sheet Components
Balance Sheet Components | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Components | Note 5 — Balance Sheet Components Our property and equipment consisted of (in thousands): December 31, 2022 2021 Property and equipment, net: Laboratory equipment $ 18,490 $ 18,837 Computer equipment and software 3,900 4,605 Office equipment, furniture and fixtures 6,056 4,042 Leasehold improvements 65,912 60,343 Construction in progress 741 224 Right-of-use assets, finance lease 2,448 1,409 Total property and equipment 97,547 89,460 Less: Accumulated depreciation ( 17,094 ) ( 16,189 ) $ 80,453 $ 73,271 Depreciation expense was $ 5.8 million , $ 2.3 million , and $ 1.8 million for 2022, 2021, and 2020, respectively. Our accrued liabilities were as follows (in thousands): December 31, 2022 2021 Accrued liabilities: Clinical and preclinical costs $ 16,105 $ 13,872 Compensation related 21,767 14,930 Other accrued expenses 6,224 5,568 Total accrued liabilities $ 44,096 $ 34,370 We sponsor a 401(k) defined contribution plan covering all employees and contributed $ 1.8 million , $ 1.1 million , and $ 0.9 million to this plan in 2022, 2021, and 2020 respectively. |
Agreements with Royalty Pharma
Agreements with Royalty Pharma | 12 Months Ended |
Dec. 31, 2022 | |
Agreements with Royalty Pharma [Abstract] | |
Agreements with Royalty Pharma | Note 6 — Agreements with Royalty Pharma On January 7, 2022, we announced that we had entered into the 2022 RPI Transactions with affiliates of Royalty Pharma International plc. The RP Loan Agreement and the RP Aficamten RPA described below, are determined to be debt instruments subsequently measured at amortized cost and were entered into with parties that were at the time of our entry into the 2022 RPI Transactions affiliated and in contemplation of one another. We used the relative fair value method and made separate estimates of the fair value of each freestanding financial instrument and then allocated the proceeds in proportion to those fair value amounts. Arrangement consideration for the RP Loan Agreement and the RP Aficamten RPA totaled $ 150 million, consisting of the two $ 50 million upfront payments for the signing of the RP Loan Agreement and the RP Aficamten RPA and milestone of $ 50 million for initiation of the first pivotal trial in oHCM for aficamten that was deemed probable at the signing of the agreements. The total consideration was allocated as follows (in thousands): Fair Value Proceeds Allocation Units of Accounting: Revenue Participation Right Purchase Agreement $ 69,498 $ 100,000 $ 89,571 Development Funding Loan Agreement 46,887 50,000 60,429 Total consideration $ 116,385 $ 150,000 $ 150,000 2022 RP Loan Agreement Under the RP Loan Agreement, we are entitled to receive up to $ 300.0 million in term loans, $ 50.0 million of which was disbursed to us on closing and the remaining $ 250.0 million available to us upon our satisfaction of customary disbursement conditions and certain development conditions by specific deadlines, as follows: • $ 50.0 million of tranche 2 term loans during the one year period following the receipt on or prior to March 31, 2023 of marketing approval from FDA of omecamtiv mecarbil; • $ 25.0 million of tranche 3 term loans during the one year period following the commercial availability of a diagnostic test measuring levels of omecamtiv mecarbil to support the final FDA label language applicable to such drug, subject to such commercial availability and the conditions to the tranche 2 term loans having occurred on or prior to March 31, 2023; • $ 75.0 million of tranche 4 term loans during the one year period following the receipt on or prior to September 30, 2024 of positive results from SEQUOIA-HCM, the Phase 3 trial for aficamten; and • $ 100.0 million of tranche 5 term loans during the one year period following the acceptance by the FDA on or prior to March 31, 2025 of an NDA for aficamten, subject to the conditions to the tranche 4 term loans having occurred on or prior to September 30, 2024. As a result of our receipt of a CRL on February 28, 2023, in connection to our NDA for omecamtiv mecarbil, we do not expect to satisfy the conditions to the availability of the tranche 2 and tranche 3 loans under the RP Loan Agreement. Each term loan under the RP Loan Agreement matures on the 10 year anniversary of the funding date for such term loan and is repayable in quarterly installments of principal, interest and fees commencing on the last business day of the seventh full calendar quarter following the calendar quarter of the applicable funding date for such term loan, with the aggregate amount payable in respect of each term loan (including interest and other applicable fees) equal to 190 % of the principal amount of the term loan for the tranche 1, tranche 4 and tranche 5 term loans and 200 % of the principal amount of the term loan for tranche 2 and tranche 3 term loans (such amount with respect to each term loan, “Final Payment Amount”). We accounted for amounts drawn under the RP Loan Agreement using the effective interest method which resulted in an effective interest rate of 7.65 % over the ten-year term. As of the date of the prepayment or maturity of the term loan (or the date such prepayment or repayment is required to be paid), we will be required to pay an additional amount equal to $ 34.6 million accreted over the term of the loan. We may prepay the term loans in full (but not in part) at any time at our option by paying an amount equal to the unpaid portion of Final Payment Amount for the outstanding term loans under the RP Loan Agreement; provided that if the conditions for either the tranche 4 term loans or the tranche 5 term loans have been met, we must have borrowed at least $ 50 million principal amount of the tranche 4 or 5 term loans. In addition, the term loans under the RP Loan Agreement are repayable in full at the option of either us or the lender in an amount equal to the unpaid portion of Final Payment Amount for the outstanding term loans upon a change of control of Cytokinetics. Future minimum payments under the existing borrowing under RP Loan Agreement are (in thousands): Years ending December 31: 2023 $ 1,440 2024 10,080 2025 11,520 2026 11,520 2027 11,520 Thereafter 48,960 Future minimum payments 95,040 Less: Unamortized interest and loan costs ( 30,272 ) Term Loan, net $ 64,768 As of December 31, 2022, the fair value of our RP Loan approximated its carrying value of $ 64.8 million based upon a market observable interest rate, which is a Level 2 input. Interest expense for the RP Loan Agreement was $ 4.8 million in 2022. Concurrent with our entry into the RP Loan Agreement, we terminated the Term Loan Agreement with Silicon Valley Bank and Oxford Finance LLC and repaid all amounts outstanding thereunder as further described in Note 7. 2022 RP Aficamten Royalty Purchase Agreement In addition, on January 7, 2022, we entered into the RP Aficamten RPA with RPI ICAV, pursuant to which RPI ICAV purchased rights to certain revenue streams from net sales of pharmaceutical products containing aficamten by us, our affiliates and our licensees in exchange for up to $ 150.0 million in consideration, $ 50.0 million of which was paid on the closing date, $ 50.0 million of which was paid to us in March 2022 following the initiation of the first pivotal trial in oHCM for aficamten and $ 50.0 million of which is payable following the initiation of the first pivotal clinical trial in nHCM for aficamten. The RP Aficamten RPA also provides that the parties will negotiate terms for additional funding if we achieve proof of concept results in certain other indications for aficamten, with a reduction in the applicable royalty if we and RPI ICAV fail to agree on such terms in certain circumstances. Pursuant to the RP Aficamten RPA, RPI ICAV purchased the right to receive a percentage of net sales equal to 4.5 % for annual worldwide net sales of pharmaceutical products containing aficamten up to $ 1 billion and 3.5 % for annual worldwide net sales of pharmaceutical products containing aficamten in excess of $ 1 billion, subject to reduction in certain circumstances (the “RP Aficamten Liability”). We account for the RP Aficamten Liability as a liability primarily because we have significant continuing involvement in generating the related revenue stream from which the liability will be repaid. If and when aficamten is commercialized and royalties become due, we will recognize the portion of royalties paid to RPI ICAV as a decrease to the RP Aficamten Liability and a corresponding reduction in cash. The carrying amount of the RP Aficamten Liability is based on our estimate of the future royalties to be paid to RPI ICAV over the life of the arrangement as discounted using an imputed rate of interest. The imputed rate of interest on the unamortized portion of the RP Aficamten Liability was approximately 22.4 % as of December 31, 2022. During the third and fourth quarter of 2022, we updated our analyses of the RP Aficamten RPA to reflect our assumptions resulting from ongoing global market research and to reflect other adjustments in connection with our anticipated commercialization. Our estimates regarding the amount of future royalty payments under the RP Aficamten RPA increased due to changes in management’s estimates of unobservable inputs related to market conditions and timing. The adjustment is accounted for on a prospective basis in our liability calculation and resulted in changes in our imputed interest rate from 11.7 % in the second quarter of 2022 to 22.4 % in the fourth quarter of 2022. We recognized $ 15.5 million of non-cash interest expense in 2022 related to the RP Aficamten RPA. In 2022, the change in estimate had no impact on revenue and increased the net loss by $ 5.3 million. The change in accounting estimate increased the net loss per share by $ 0.06 in 2022. 2017 RP Omecamtiv Mecarbil Royalty Purchase Agreement In February 2017, we entered into the RP OM RPA pursuant to which we sold a portion of our right to receive royalties from Amgen on future net sales of omecamtiv mecarbil to RPFT for a one-time payment of $ 90 million, which is non-refundable even if omecamtiv mecarbil is never commercialized. Concurrently, we entered into a common stock purchase agreement with RPFT through which RPFT purchased 875,656 shares of the Company’s common stock for $ 10.0 million. We allocated the consideration and issuance costs on a relative fair value basis to our liability to RPFT related to sale of future royalties under the RP OM RPA (the “RP OM Liability”) and the common stock sold to RPFT, which resulted in the RP OM Liability being initially recognized at $ 92.3 million. The RP OM RPA provides for the sale of a royalty to RPFT of 4.5 % on worldwide net sales of omecamtiv mecarbil, subject to a potential increase of up to an additional 1 % under certain circumstances. As a result of our receipt of a CRL on February 28, 2023 in connection to our NDA for omecamtiv mecarbil, pursuant to the terms of the RP OM RPA, the applicable royalty rate will increase to a maximum of 5.5 % if omecamtiv approval obtains FDA approval at any time after June 30, 2023. As a result of the termination of the Amgen Agreement and pursuant to our obligations under the RP OM RPA, we and RPFT amended the RP OM RPA on January 7, 2022 to preserve RPFT’s rights under the RP OM RPA by providing for direct payments by us to RPFT of up to 5.5 % of our and our affiliates and licensees worldwide net sales of omecamtiv mecarbil. The RP OM RPA, as amended, had no impact on the original accounting for the $ 92.3 million associated with the RP OM Liability established in February 2017. We account for the RP OM Liability as a liability primarily because we have significant continuing involvement in generating the related revenue stream from which the liability will be repaid. If and when omecamtiv mecarbil is commercialized and royalties become due, we will recognize the portion of royalties paid to RPFT as a decrease to the RP OM Liability and a corresponding reduction in cash. The carrying amount of the RP OM Liability is based on our estimate of the future royalties to be paid to RPFT over the life of the arrangement as discounted using an imputed rate of interest. The excess of future estimated royalty payments over the $92.3 million of allocated proceeds, less issuance costs, is recognized as non-cash interest expense using the effective interest method. The imputed rate of interest on the unamortized portion of the RP OM Liability was approximately 8.5 % as of December 31, 2022 and 10.0 % as of December 31, 2021. During the third and fourth quarter of 2022, we updated our analyses of the RP OM RPA to reflect our current assumptions resulting from ongoing global market research and to reflect other adjustments in connection with our anticipated commercialization, including the result of FDA Cardiovascular and Renal Drugs Advisory Committee in December 2022 that voted the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of HFrEF. Our estimates regarding the amount of future royalty payments under the RP OM RPA decreased year over year, however the royalty rate and probability of success increased from 2021 to 2022. The adjustments are accounted for on a prospective basis in our liability calculation and resulted in changes in our imputed interest rate and non-cash interest expense from 10.0 % and $ 12.9 million in 2021 to 8.5 % and $ 16.2 million in 2022, respectively. In 2022, the change in estimate had no impact on revenue and reduced the net loss by $ 1.8 million. The change in accounting estimate reduced the net loss per share by $ 0.02 in 2022. As a result of our receipt of a CRL in connection to our NDA for omecamtiv mecarbil (see Note 11), our estimates regarding the amount of future royalty payments under the RP OM RPA will be re-evaluated in the first quarter of 2023 and will be accounted for on a prospective basis in our liability calculation. As a consequence of our receipt of the CRL from FDA, any approval of omecamtiv mecarbil in the United States would likely only occur after June 30, 2023, the date at which the royalty rate under the RP OM RPA will increase to no more than 5.5 %, while and the resulting sales forecast for omecamtiv mecarbil is expected to decrease since comercializaation and sales of omecamtiv mecarbil will be delayed. Accounting for the Royalty Pharma Royalty Purchase Agreements We periodically assess the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than its original estimates, we will prospectively adjust the amortization of the RP OM Liability and the RP Aficamten Liability and the effective interest rate. There are a number of factors that could materially affect the amount and timing of royalty payments, a number of which are not within our control. The RP OM Liability and the RP Aficamten Liability are recognized using significant unobservable inputs. These inputs are derived using internal management estimates developed based on third party data, including competitor sales data, and reflect management’s judgements, current market conditions surrounding competing products, and forecasts. The significant unobservable inputs include the estimated patient population, estimated selling price, estimated peak sales and sales ramp, the expected term of the royalty stream, timing of the expected launch and its impact on the royalty rate as well as the overall probability of success. A significant change in unobservable inputs could result in a material increase or decrease to the effective interest rate of the RP OM Liability and the RP Aficamten Liability. We review our assumptions on a regular basis and our estimates may change in the future as we refine and reassess our assumptions. Changes to the RP Aficamten Liability and the RP OM Liability are as follows (in thousands) : 2022 2021 RP Aficamten Liability RP OM Liability RP OM Liability Beginning balance, January 1 $ — $ 179,072 $ 166,068 Initial carrying value 89,571 — — Interest accretion 15,546 16,196 12,892 Amortization of issuance costs — 116 112 Ending balance, December 31 $ 105,117 $ 195,384 $ 179,072 As of December 31, 2022, the fair value of the liabilities related to the sale of future royalties to RPFT and RPI ICAV are consistent with their carrying values of $ 105.1 million and $ 195.4 million , respectively, and is based on our estimates of the amount and timing of future royalties expected to be paid to RPFT and RPI ICAV under the RP OM RPA and the RP Aficamten RPA agreements, respectively, as defined above, over the life of the arrangement, which are considered Level 3 inputs. We recognized $ 31.7 million , $ 12.9 million , and $ 22.7 million in non-cash interest expense in 2022, 2021, and 2020 , respectively, related to the RP Aficamten RPA and the RP OM RPA. |
Debt
Debt | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
Debt | Note 7 — Debt Silicon Valley Bank and Oxford Finance Term Loans Prior to January 7, 2022, we maintained the Term Loan Agreement with Silicon Valley Bank and Oxford Finance LLC. Both borrowings under the Term Loan Agreement were subject to interest at an annual rate equal to the greater of (a) 8.05 % or (b) the sum of 6.81 % plus the 30-day U.S. LIBOR rate. The borrowing under the Term Loan Agreement was repayable in monthly interest-only payments through December 31, 2020. The interest-only period was automatically extended until July 1, 2021 as a result of the Company’s initiation of a Phase 2 trial for aficamten in oHCM and was extended through December 31, 2021 as a result of the achievement of positive results in GALACTIC-HF, the trial of omecamtiv mecarbil in chronic heart failure as announced on October 8, 2020. The ultimate interest-only period was to be followed by equal monthly payments of principal and interest to the maturity date in December 2023. We were required to make a final payment upon loan maturity of 6.00 % of the notes payable, which we accreted over the life of the Term Loan Agreement. Our obligations under the Term Loan Agreement were secured by substantially all our current and future assets, other than our intellectual property. The Term Loan Agreement was terminated, and all amounts thereunder repaid in connection to our entry into that certain RP Loan Agreement, between us and RPDF, as further described below. Amounts outstanding under the Term Loan Agreement were classified as non-current in our consolidated balance sheet as of December 31, 2021, because short-term obligations expected to be refinanced on a long-term basis are not expected to require the use of working capital during the ensuing fiscal year. As a result of the termination of the Term Loan Agreement and the repayment to the Lenders, in 2022, we recorded $ 2.7 million in loss on debt extinguishment in the consolidated statements of operations and comprehensive loss, consisting of the premium on debt repayments and the write-off of the remaining term loan fees and debt issuance costs. Interest expense for the Term Loan Agreement was immaterial for 2022 because it represented approximately one week of interest before extinguishment. Interest expense for the Term Loan Agreement was $ 4.8 million and $ 4.9 million for 2021 and 2020 respectively. Convertible Notes On November 13, 2019, the Company issued $ 138.0 million aggregate principal amount of 2026 Notes. On July 6, 2022, the Company issued $ 540.0 million aggregate principal amount of 2027 Notes and used approximately $ 140.3 million of the net proceeds from the offering of 2027 Notes and issued 8,071,343 shares of common stock to repurchase approximately $ 116.9 million aggregate principal amount of the 2026 Notes pursuant to privately negotiated exchange agreements entered into with certain holders of the 2026 Notes concurrently with the pricing of the offering of the 2027 Notes. As a result of the partial repurchase of the 2026 Notes, the Company recorded an inducement loss of $ 22.2 million, consisting of the difference between the consideration to the holders pursuant to the exchange agreements and the if-converted value of the 2026 Notes under the original terms. As of December 31, 2022 , there remain $ 21.1 million aggregate principal amount of 2026 Notes outstanding. The 2026 Notes are unsecured obligations and bear interest at an annual rate of 4.0 % per year, payable semi-annually on May 15 and December 15 of each year, beginning May 15, 2020 . The 2026 Notes are governed by an indenture between the Company and U.S. Bank National Association, as trustee. The 2026 Notes will mature on November 15, 2026 , unless earlier repurchased or redeemed by the Company or converted at the option of the holders. The Company may redeem the 2026 Notes prior to the maturity date but is not required to and no sinking fund is provided for the 2026 Notes. The 2026 Notes may be converted, under certain circumstances as described below, based on an initial conversion rate of 94.7811 shares of common stock per $ 1,000 principal amount (which represents an initial conversion price of $ 10.55 per share). The conversion rate for the 2026 Notes will be subject to adjustment upon the occurrence of certain specified events. In addition, upon the occurrence of a make-whole fundamental change (as defined in the indenture), the Company will, in certain circumstances, increase the conversion rate by a number of additional shares for a holder that elects to convert its notes in connection with such make-whole fundamental change. The Company received approximately $ 133.9 million in net proceeds, after deducting the initial purchasers’ discount, from the issuance of the 2026 Notes. The 2026 Notes may be converted at the option of the holder under any of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds 127.5 % of the last reported sale price of the Company’s common stock on November 7, 2019; (2) during the 5 consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) if the trading price per $ 1,000 principal amount of 2026 Notes for each trading day of the measurement period was less than 98 % of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company’s common stock; (4) if the Company calls the 2026 Notes for redemption; and (5) at any time from, and including, July 15, 2026 until the close of business on the scheduled trading day immediately before the maturity date, November 15, 2026. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate. The 2026 Notes are convertible at December 31, 2022 based on circumstance (1) defined above. The 2026 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after November 20, 2023 and, in the case of any partial redemption, on or before the 60th scheduled trading day before the maturity date, at a cash redemption price equal to the principal amount of the 2026 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. If a “fundamental change” (as defined in the indenture agreement, dated November 13, 2019 between the Company and U.S. Bank National Association, as trustee, as supplemented by the first supplemental indenture dated as of November 13, 2019 between the Company and such trustee) occurs, then, subject to certain exceptions, holders may require the Company to repurchase their 2026 Notes at a cash repurchase price equal to the principal amount of the 2026 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. As discussed in Note 1, effective January 1, 2022, the Company adopted ASU 2020-06 using the modified retrospective method and, as a result, it is no longer required to separately account for the liability and equity components of the 2026 Notes, and, instead, account for the 2026 Notes wholly as debt. The following table presents the total amount of interest cost recognized relating to the 2026 Notes (in thousands): Years Ended December 31, 2022 2021 2020 Contractual interest expense $ 3,265 $ 5,520 $ 5,520 Accretion of debt discount — 5,907 5,246 Accretion of debt issuance costs 355 59 52 Total interest costs recognized $ 3,620 $ 11,486 $ 10,818 The effective interest rate of the 2026 Notes was 4.6 % for the year ended December 31, 2022. As of December 31, 2022, the unamortized debt issuance cost for the 2026 Notes was $ 0.5 million and will be amortized over approximately 3.9 years. If the 2026 Notes were to be converted on December 31, 2022, the holders of the 2026 Notes would receive common shares of 2.6 million with an aggregate value of $ 117.0 million based on the Company’s closing stock price of $ 45.82 as of December 31, 2022. The if-converted value of the 2026 Notes exceeded its principal amount by $ 95.9 million as of December 31, 2022. The 2027 Notes are the Company’s senior, unsecured obligations and are (i) senior in right of payment to the Company’s future indebtedness that is expressly subordinated to the 2027 Notes in right of payment; (ii) equal in right of payment with all of the Company’s indebtedness that is not so subordinated (including the 2026 Notes); (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. The net proceeds of the 2027 Notes were approximately $ 523.6 million after deducting issuance costs related to the 2027 Notes. The 2027 Notes bear interest at a rate of 3.50 % per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2023 . The 2027 Notes will mature on July 1, 2027 , unless earlier converted, redeemed or repurchased. The 2027 Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate(s). The initial conversion rate for the 2027 Notes is 19.5783 shares of the Company’s Common Stock per $ 1,000 principal amount of such Notes, which is equivalent to an initial conversion price of approximately $ 51.08 per share. Holders of the 2027 Notes may convert all or any portion of their convertible notes at their option only in the following circumstances: (i) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2022, if the last reported sale price per share of the Company’s common stock, $ 0.001 par value per share, exceeds 130 % of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (ii) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) if the trading price per $ 1,000 principal amount of 2027 Notes for each trading day of the measurement period was less than 98 % of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (iii) upon the occurrence of certain corporate events or distributions on the Company’s common stock, as described in the 2027 Indenture; (iv) if the Company calls such 2027 Notes for redemption; and (v) at any time from, and including, March 1, 2027 until the close of business on the scheduled trading day immediately before the maturity date. The Company may not redeem the 2027 Notes at its option at any time before July 7, 2025. The 2027 Notes will be redeemable, in whole or in part (subject to the “Partial Redemption Limitation” (as defined in the 2027 Indenture)), at the Company’s option at any time, and from time to time, on or after July 7, 2025 and, in the case of a partial redemption, on or before the 60th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any of the 2027 Notes for redemption will constitute a Make-Whole Fundamental Change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. The conversion rate for the 2027 Notes shall not exceed 25.4517 shares per $ 1,000 principal amount of such Notes, subject to certain customary anti-dilution adjustments (as defined in the 2027 indenture). Pursuant to the Partial Redemption Limitation, the Company may not elect to redeem less than all of the outstanding 2027 Notes unless at least $ 75.0 million aggregate principal amount of 2027 Notes are outstanding and not subject to redemption as of the time the Company sends the related redemption notice. If a “Fundamental Change” (as defined in the 2027 Indenture) occurs, then, subject to a limited exception for certain cash mergers, noteholders may require the Company to repurchase their 2027 Notes at a cash repurchase price equal to the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company’s common stock. In accounting for the Notes, issuance costs of $ 16.4 million for the 2027 Notes were deducted from the respective debt liability in the consolidated balance sheet. Issuance costs are amortized to interest expense using the straight-line method, which materially approximates the effective interest method, over five-year term for the 2027 Notes. The following table presents the total amo unt of interest cost recognized relating to the 2027 Notes (in thousands): 2022 Contractual interest expense $ 9,188 Amortization of debt issuance costs 1,542 Total interest expense recognized $ 10,730 The effective interest rate of the 2027 Notes was 4.17 % in 2022. As of December 31, 2022, the unamortized debt issuance cost for the 2027 Notes was $ 14.9 million and will be amortized over approximately 4.6 years. If the 2027 Notes were to be converted on December 31, 2022, the holders of the 2027 Notes would receive common shares of 10.5 million with an aggre gate value of $ 484.4 million based on the Company’s closing stock price of $ 45.82 as of December 31, 2022. The if-converted value of the 2027 Notes was below the principal value of the Notes of $ 540.0 million as of December 31, 2022. In addition, in 2022, the conditions allowing holders of the Notes to convert were not met. As a result, the Notes were not convertible at December 31, 2022 nor at any point during 2022. Future minimum payments under the 2027 Notes and 2026 Notes are (in thousands): Years ending December 31: 2027 Notes 2026 Notes Total 2023 $ 9,450 $ 845 $ 10,295 2024 18,900 845 19,745 2025 18,900 845 19,745 2026 18,900 21,978 40,878 2027 558,900 — 558,900 Future minimum payments 625,050 24,513 649,563 Less: Interest ( 85,050 ) ( 3,381 ) ( 88,431 ) Convertible notes, principal amount 540,000 21,132 561,132 Less: Debt costs on the convertible notes ( 14,871 ) ( 453 ) ( 15,324 ) Net carrying amount of the convertible notes $ 525,129 $ 20,679 $ 545,808 As of December 31, 2022, the estimated fair value of the 2027 Notes and 2026 Notes was $ 620.3 million and $ 94.8 million , respectively, and was based upon observable, Level 2 inputs, including pricing information from recent trades of the convertible notes. Capped Call Transactions In connection with the offering of the 2026 Notes, the Company entered into privately-negotiated capped call transactions with one of the underwriters in the offering or its affiliate. The Company used approximately $ 13.4 million of the net proceeds from the offering of the 2026 Notes to pay the cost of the capped call transactions. The capped call transactions were expected generally to reduce potential dilution to the Company’s common stock upon any conversion of the 2026 Notes and/or offset any cash payments the Company would have been required to make in excess of the principal amount of converted 2026 Notes, as the case may be, in the event that the market value per share of the Company’s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the 2026 Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $ 14.07 per share (which represents a premium of approximately 70 % over the last reported sale price of the Company’s common stock on November 7, 2019), subject to certain adjustments. The capped call transactions were separate transactions, entered into by the Company and were not part of the terms of the 2026 Notes. Given that the transactions meet certain accounting criteria, the convertible note capped call transactions were recorded in stockholders’ equity, they were not accounted for as derivatives and were not remeasured each reporting period. On October 24, 2022, we entered into a termination agreement in connection to the capped call transactions and thereby released the capped call counterparties of any further obligations in relation to the capped call transactions. As a result of the termination agreement and unwinding of the capped call transactions, we received gross proceeds of $ 26.4 million in cash. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 31, 2022 | |
Equity [Abstract] | |
Stockholders' Equity | Note 8 — Stockholders’ Equity Equity Incentive Plan Our 2004 Plan provides for us to grant incentive stock options, nonstatutory stock options, restricted stock, stock appreciation rights, restricted stock units, performance shares and performance units to employees, directors, and consultants. We may grant options for terms of up to ten years at prices not lower than 100 % of the fair market value of our common stock on the date of grant. Options granted to new employees generally vest 25 % after one year and monthly thereafter over a period of four years . Options granted to existing employees generally vest monthly over a period of four years . In May 2022, our stockholders approved an amendment to the 2004 Plan to increase the number of authorized shares reserved for issuance under the 2004 Plan by an additional 6.0 million shares. In May 2022, our board of directors approved an amendment to the 2004 Plan to increase the number of authorized shares reserved for issuance under the 2004 Plan by an additional 1.6 million shares for inducement grants to new employees. As of December 31, 2022, the total authorized shares under the 2004 Plan available for grant was 9.7 million . Stock option activity in 2022, 2021, and 2020 was as follows: Stock Options Weighted Weighted Aggregate Balance at December 31, 2019 7,759,012 $ 8.59 Granted 1,944,562 15.59 Exercised ( 967,571 ) 8.27 Forfeited ( 234,054 ) 16.06 Balance at December 31, 2020 8,501,949 $ 10.02 Granted 2,513,350 22.43 Exercised ( 1,346,194 ) 9.01 Forfeited ( 296,146 ) 14.56 Balance at December 31, 2021 9,372,959 $ 13.35 Granted 3,424,150 39.79 Exercised ( 1,389,031 ) 10.13 Forfeited ( 415,675 ) 28.94 Balance at December 31, 2022 10,992,403 $ 22.13 7.0 $ 261.9 Exercisable at December 31, 2022 6,153,725 $ 13.21 5.6 $ 200.7 We have elected to account for forfeitures as they occur. The intrinsic value of stock options exercised, calculated based on the difference between the market value at the date of exercise and the exercise price, was $ 46.3 million for 2022, $ 29.3 million for 2021, and $ 14.0 million for 2020. The intrinsic value of stock options outstanding at December 31, 2022 was $ 261.9 million . RSU, including PSU , activity in 2022, 2021, and 2020 was as follows: Number of Weighted Balance at December 31, 2019 839,075 $ 7.49 Granted 731,225 14.40 Exercised ( 435,450 ) 7.72 Forfeited ( 18,208 ) 10.37 Balance at December 31, 2020 1,116,642 $ 11.88 Granted 1,093,450 21.69 Exercised ( 606,240 ) 11.13 Forfeited ( 189,025 ) 21.32 Balance at December 31, 2021 1,414,827 $ 18.52 Granted 780,519 37.69 Exercised ( 707,772 ) 16.72 Forfeited ( 273,310 ) 26.65 Balance at December 31, 2022 1,214,264 $ 30.07 RSUs generally vest annually over two to three years . For 2022, the fair value of RSUs vested, calculated based on the units vested multiplied by the closing price of our common stock on the date of vesting, was $ 26.2 million . Performance Stock Units In May 2021, the Compensation Committee granted a total of 375,000 PSUs to certain employees with a weighted average grant date fair value of $ 25.32 per unit. The fair value of the PSUs was determined on the grant date based on the fair value of the Company’s common stock at such time. The PSUs consist of two equal tranches with 50 % of each tranche vesting upon achieving certain performance criteria and 50 % vesting at the one-year anniversary of such achievement provided the recipient has been continuously employed by the Company. The first tranche vests upon certification by the Compensation Committee that the NDA for omecamtiv mecarbil has been filed and accepted by the FDA by December 31, 2021 or June 30, 2022 and the second tranche vests upon certification by the Compensation Committee that the FDA approval of the NDA is with an approved label that is consistent with the expectations underlying the Company’s commercial launch plans for omecamtiv mecarbil in effect immediately prior to such approval by June 30, 2022 or December 31, 2022. In 2022, the performance target for the first tranche of PSUs was met. As a result, the Company recognized expense of $ 0.7 million in 2022 for the first tranche of PSUs. No expense has been recognized for the second tranche to date. The performance target for the second tranche of PSUs has not been met, and therefore, such second tranche of PSUs consisting of 182,500 PSUs are deemed forfeited. As of December 31, 2022, there was $ 0.1 million of unamortized stock-based compensation related to the first tranche. Employee Stock Purchase Plan Under our ESPP, employees may purchase common stock up to a specified maximum amount at a price equal to 85 % of the fair market value at certain plan-defined dates. In May 2020, the Company’s stockholders approved an amendment to the ESPP to increase the number of common stock shares reserved for issuance under the ESPP by 0.5 million shares. We issued 98,153 shares at an average price of $ 32.89 per share during 2022, 108,780 shares at an average price of $ 16.33 per share in 2021, and 134,684 shares at an average price of $ 11.21 per share in 2020 pursuant to the ESPP. At December 31, 2022, we have 239,887 shares of common stock reserved for issuance under the ESPP. Stock-Based Compensation Expense We use the Black-Scholes option pricing model to determine the fair value of stock option grants to employees and directors and employee stock purchase plan shares. The fair value of share-based payments was estimated on the date of grant based on the following assumptions: Year Ended December Year Ended December Year Ended December Options ESPP Options ESPP Options ESPP Risk-free interest rate 1.41 % to 4.01 % 1.63 % to 4.65 % 0.58 % to 1.28 % 0.05 % 0.42 % to 1.8 % 0.11 % to 1.8 % Volatility 66 % to 67 % 64 % to 65 % 66 % to 67 % 66 % to 67 % 74 % to 75 % 74 % to 75 % Expected term in years 6.3 to 6.4 0.5 6.4 to 6.5 0.5 6.5 to 6.6 0.5 Expected dividend yield 0 % 0 % 0 % 0 % 0 % 0 % We use U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options for the risk-free interest rate. We use our own volatility history based on its stock’s trading history and our own historical exercise and forfeiture activity to estimate expected term for option grants. We do not anticipate paying dividends in the foreseeable future and use an expected dividend yield of zero. We do not estimate forfeitures in our stock-based compensation. We measure compensation expense for restricted stock units at fair value on the date of grant and recognize the expense over the expected vesting period. We recognize stock-based compensation expense on a ratable basis over the requisite service period, generally the vesting period of the award for share-based awards. Stock-based compensation expense for 2022, 2021, and 2020 was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Research and development $ 19,100 $ 10,463 $ 6,949 General and administrative 28,753 16,369 10,671 $ 47,853 $ 26,832 $ 17,620 Stock-based compensation expense for share-based awards to non-employees was $ 0.1 million in 2022, and $ 0.2 million in 2021, and 2020. As of December 31, 2022, we expect to recognize $ 94.4 million of unrecognized compensation cost related to unvested stock options over a weighted-average period of 2.8 years, $ 20.5 million of unrecognized compensation cost related to unvested restricted stock over a weighted-average period of 1.5 years, and $ 0.1 million of unrecognized compensation cost related to the first tranche of PSUs. Warrants In May 2022, Silicon Valley Bank exercised 16,901 warrants issued pursuant to the Term Loan Agreement with a strike price of $ 7.10 per share and elected the cashless settlement method. In June 2022, Silicon Valley Bank exercised additional 9,226 warrants and 8,638 warrants with a strike price of $ 9.76 per share and $ 10.42 per share, respectively. Accordingly, in 2022, we issued to Silicon Valley Bank a total of 28,306 shares of our common stock. As of December 31, 2022, we had the following outstanding warrants issued pursuant to the Term Loan Agreement with a weighted average exercise price of $ 10.42 per share to purchase 12,957 shares of our common stock: Issuance Date Expiration Date Exercise Price Warrants Exercised during Warrants Outstanding at January 2020 January 2030 $ 10.42 8,638 12,957 May 2019 May 2029 9.76 9,226 — August 2018 August 2028 7.10 16,901 — 34,765 12,957 As of December 31, 2021 and 2020, we had the following outstanding warrants issued pursuant to the Term Loan Agreement with a weighted average exercise price of $ 9.12 per share to purchase 47,722 shares of our common stock: o Issuance Date Expiration Date Exercise Price Warrants Outstanding at Warrants Exercised during Warrants Outstanding at January 2020 January 2030 $ 10.42 — — 21,595 May 2019 May 2029 9.76 23,065 13,839 9,226 August 2018 August 2028 7.10 42,253 25,352 16,901 February 2016 February 2026 6.59 51,214 51,214 — October 2015 October 2025 6.90 48,892 48,892 — 165,424 139,297 47,722 Claims Settlement In the first quarter of 2020, we received $ 2.2 million from a claims settlement with certain institutional investors that were beneficial owners of our common stock related to the disgorgement of short swing profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended. This settlement was recognized in equity as additional paid-in capital. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 9 — Commitments and Contingencies Operating Leases In May 2021, we amended the lease agreement for buildings 250, 256 and 280 East Grand Avenue, South San Francisco, California for our existing facilities and extended the lease term until June 30, 2022 , which was accounted for as a lease modification in accordance with ASC 842, Leases . Pursuant to such guidance, the Company remeasured the modified lease using the revised term as of the modification date. Adjustments were made to reflect the remeasured liability with the offset to the right-of-use asset. The lease includes rental payments and payment of certain operating expenses. During the fourth quarter of 2021, we officially relocated from our old headquarters to our new facilities at Oyster Point. As a result of the relocation, we considered ceasing use of the existing headquarters, which triggered an impairment assessment. In connection with this assessment, we recorded an impairment loss of $ 2.8 million , consisting of right-of-use assets of the existing headquarters, which is included in operating expenses on the consolidated statement of operations for the year ended December 31, 2021. No expense was recognized in 2022 due to the impairment that was recorded in 2021. We were subject to the fixed rental fee payments for the existing headquarters until the lease expired in June 2022. In July 2019, we entered into the Oyster Point Lease of office and laboratory space at a facility located in South San Francisco, California and in May 2020, January 2021, November 2021, and October 2022, we entered into first, second, third, and fourth amendments to the Oyster Point Lease. The Oyster Point Lease commenced on March 31, 2021 and upon commencement, we recognized a right-of-use asset of $ 77.9 million, a short-term lease liability of $ 3.7 million and a long-term lease liability of $ 85.3 million. The long-term lease liability includes $ 11.1 million of tenant improvement reimbursements as of March 31, 2021. The Oyster Point Lease has expiration date of October 31, 2033 and we have two consecutive five-year options to extend the lease. The options to extend the lease term were not included as part of the right-of-use asset or lease liability as the exercise of the options were not reasonably assured at the inception of the lease. During the fourth quarter of 2022, we entered into the fourth amendment of the lease to amend the lease payment schedule, which increased the remaining lease payment through the lease expiration date. The amendments were accounted for as lease modifications in accordance with ASC 842. As of December 31, 2022, the remaining lease term of the Oyster Point Lease is 10.8 years and the discount rate used to determine the related lease liability was 8.7 % . We paid a total security deposit of $ 5.1 million in December 2019 and December 2020. The landlord has provided a tenant improvement allowance of $ 43.6 million in aggregate for costs relating to the initial design and construction of the improvements. As of December 31, 2022, the total commitment of undiscounted lease payments for the Oyster Point Lease was $ 220.4 million . In January 2022, we entered into a series of lease agreements with the sub-landlord and landlord and leased an office space at a facility located in Radnor, Pennsylvania (the "Radnor Lease"). The Radnor Lease commenced on September 1, 2022 , when the leasehold improvements were substantially completed, and we gained a control over the use of the underlying assets. Upon commencement, we recognized a right-of-use asset of $ 3.4 million, a short-term lease liability of $ 0.4 million and a long-term lease liability of $ 1.9 million. The right-of-use asset includes $ 1.1 million of lease prepayments made before the commencement date. We will pay certain operating costs of the facility and have certain rights to sublease under the agreement. The Radnor Lease had an initial expiration date of May 31, 2024 with the sub-landlord. We will then continue to lease the premises with the landlord through July 31, 2027 with one five-year option to extend the lease. The option to extend the lease term were not included as part of the right-of-use asset or lease liability as the exercise of the options were not reasonably assured at the inception of the lease. As of December 31, 2022, the remaining lease term of the Radnor Lease is 4.6 years and the discount rate used to determine the related lease liability was 8.3 %. We have incurred a tenant improvement cost of $ 1.2 million relating to the initial design and construction of the improvements before the commencement date. The tenant improvement cost is offset by a tenant improvement allowance of $ 0.3 million from the landlord, and the net tenant improvement cost incurred before the commencement date is accounted for lease prepayment. The total commitment of undiscounted lease payments for the Radnor Lease was $ 2.8 million as of December 31, 2022. Cash paid for operating lease for the years ended December 31, 2022 and 2021 was $ 24.1 million and $ 6.1 million , respectively, and was included in net cash used in operating activities in our consolidated statements of cash flows. Finance Leases During the third quarter of 2021, we entered into a master lease agreement for laboratory equipment leases that commenced in the fourth quarter of 2021. The leases have an initial term of 3 years , commenced through the second quarter of 2022 and expire in 2025. The master lease agreement provides a purchase option with a bargain purchase price, which we expect to exercise at the end of the term. The Company classified the leases as finance leases. Finance leases are accounted for on the consolidated balance sheets with right-of-use assets and lease liabilities recognized in property and equipment, other current liabilities, and other non-current liabilities, respectively. The finance lease cost is recognized as a combination of the amortization expense for the right-of-use assets calculated on a straight-line basis over the five-year estimated useful life for laboratory equipment and interest expense for the outstanding lease liabilities using the determined discount rates. As of December 31, 2022 , we have recognized finance lease right-of-use assets of $ 2.4 million , short-term finance lease liabilities of $ 1.0 million , and long-term finance lease liabilities of $ 1.0 million . As of December 31, 2022, the weighted average remaining lease term for the finance leases is 4.0 years and the weighted average discount rate used to determine the finance lease liabilities is 9.47 % . The cash paid for finance lease for the year ended December 31, 2022 was $ 0.9 million and was included in financing activities in our consolidated statement of cash flows. Future minimum lease payments under non-cancellable leases as of December 31, 2022 is as follows (in thousands): Years ending December 31: Operating Leases Finance Leases 2023 $ 13,465 $ 990 2024 18,738 990 2025 19,563 204 2026 20,180 — 2027 20,514 — Thereafter 130,719 — Total future minimum lease payments 223,179 2,184 Less: Imputed interest ( 83,455 ) ( 183 ) Total lease liability $ 139,724 $ 2,001 Rent expense for operating and finance leases was $ 21.6 million , $ 23.1 million , and $ 5.7 million for 2022, 2021, and 2020 , respectively. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 10 — Income Taxes We did no t record an income tax provision in 2022, 2021, and 2020 because we had net taxable losses. Our significant jurisdictions are the United States and California. The following reconciles the statutory federal income tax rate to our effective tax rate: Years Ended December 31, 2022 2021 2020 Tax at federal statutory tax rate 21 % 21 % 21 % State tax, net of federal benefits 1 % 0 % 1 % Change in state effected rates 0 % ( 1 )% ( 2 )% Tax credits, net 4 % 3 % 3 % Change in valuation allowance ( 26 )% ( 24 )% ( 23 )% Stock-based compensation 2 % 2 % 1 % Other ( 2 )% ( 1 )% ( 1 )% Total 0 % 0 % 0 % Deferred tax assets, net, reflecting the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, were as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 202,459 $ 181,977 Tax credits 98,292 77,366 Liability related to sale of future royalties 68,366 38,302 Reserves and accruals 23,950 15,409 Capitalized R&D 48,047 1,115 Long-term lease liability 28,901 26,223 Deferred revenue — 18,608 Total noncurrent deferred tax assets 470,015 359,000 Deferred tax liabilities: Depreciation and amortization ( 7,909 ) ( 7,664 ) Operating lease right-of-use assets ( 18,192 ) ( 15,643 ) Convertible notes — ( 8,296 ) Total noncurrent deferred tax liabilities ( 26,101 ) ( 31,603 ) Less: Valuation allowance ( 443,914 ) ( 327,397 ) Net deferred tax assets $ — $ — Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception, expected future losses, and difficulty in accurately forecasting our future results and an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable, we maintained a full valuation allowance on the net deferred tax assets as of December 31, 2022 and 2021. The valuation allowance increased by $ 116.5 million in 2022 and increased by $ 52.6 million in 2021. At December 31, 2022 federal NOL carryforwards were $ 834.4 million and apportioned state NOL carryforwards before federal benefits were $ 367.1 million . If not utilized, federal and state operating loss carryforwards incurred prior to 2018 will begin to expire in various amounts beginning 2022 and 2028 , respectively. At December 31, 2022, tax credits of $ 99.4 million and $ 21.0 million for federal and California income tax purposes, respectively consisted of Research and Development Credits and Orphan Drug Credits. If not utilized, the federal carryforwards will expire in various amounts beginning in 2022 . California based credit carryforwards do not expire. In general, under Section 382, a corporation that undergoes an ‘ownership change’ is subject to limitations on its ability to utilize its pre-change net operating losses and tax credits to offset future taxable income. We do not believe it has experienced an ownership change since 2006, however, a portion of its NOLs and tax credits prior to 2007 will be subject to limitations under Section 382. Activity related to our gross unrecognized tax benefits were (in thousands): Years Ended December 31, 2022 2021 2020 Balance at the beginning of the year $ 11,295 $ 10,522 $ 9,922 Increase related to prior year tax positions 4,438 — — Decrease related to prior year tax positions ( 1,804 ) ( 29 ) ( 3 ) Increase related to current year tax positions 4,426 802 603 Balance at the end of the year $ 18,355 $ 11,295 $ 10,522 We are subject to federal and various state and local income tax examination for all fiscal years with unutilized NOLs and tax credit carryforwards. Included in the balance of unrecognized tax benefits as of December 31, 2022, 2021, and 2020 are $ 17.7 million , $ 10.3 million , and $ 9.6 million of tax benefits, respectively, that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law making several changes to the Internal Revenue Code, including provisions addressing the carryback of net operating losses for specific periods, refunds of alternative minimum tax credits, temporary modifications to limitations placed on the tax deductibility of net interest expenses, and technical amendments for qualified improvement property. Additionally, the CARES Act provides for refundable employee retention tax credits and the deferral of the employer-paid portion of Social Security taxes. For the years ended December 31, 2022, 2021, and 2020, respectively, the Company’s income tax provision was not significantly impacted by the CARES Act. The Inflation Reduction Act of 2022, or IRA, was signed into law on August 16, 2022. The bill was meant to address the high inflation rate in the United States through various climate, energy, healthcare, and other incentives. These incentives are meant to be paid for by the tax provisions included in the IRA, such as a new 15 percent corporate minimum tax, a 1 percent new excise tax on stock buybacks, additional IRS funding to improve taxpayer compliance, and others. The IRA provisions are effective for tax years beginning after December 31, 2022. At this time, none of the IRA tax provisions are expected to have a material impact to our consolidated tax provision for the year ending December 31, 2023. The Company will continue to closely monitor any effects from future legislation. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 11 — Subsequent Events CRL in response to our NDA for omecamtiv mecarbil On February 28, 2023, we announced that we received a CRL from the FDA’s Division of Cardiology and Nephrology regarding our NDA for omecamtiv mecarbil for the treatment of HFrEF. According to the CRL, GALACTIC-HF is not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, in lieu of evidence from at least two adequate and well-controlled clinical investigations. In addition, FDA stated that results from an additional clinical trial of omecamtiv mecarbil are required to establish substantial evidence of effectiveness for the treatment of HFrEF, with benefits that outweigh the risks. FDA’s decision to issue a CRL follows an FDA Cardiovascular and Renal Drugs Advisory Committee’s vote of 8 to 3 in December 2022 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of HFrEF. Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. On March 1, 2023, we entered into an amended and restated Controlled Equity Offering SM Sales Agreement (the “Amended ATM Facility”), with Cantor Fitzgerald & Co. (“Cantor”), under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share (“the Common Stock”) having an aggregate offering price of up to $300.0 million through Cantor, as sales agent. The Amended ATM Facility amends, restates and supersedes the Controlled Equity Offering SM Sales Agreement dated as of March 6, 2019 between the Company and Cantor. Cantor may sell the Common Stock by any method that is deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Global Select Market or any other trading market for our common stock. Cantor will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay Cantor a commission of up to 3.0% of the aggregate gross sales proceeds of any common stock sold through Cantor under the Amended ATM Facility, and also have provided Cantor with customary indemnification rights. |
Organization and Accounting P_2
Organization and Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization | Organization Cytokinetics, Incorporated (the “Company”, “we” or “our”) was incorporated under the laws of the state of Delaware on August 5, 1997. We are a late-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Our financial statements contemplate the conduct of our operations in the normal course of business. We have incurred an accumulated deficit of approximately $ 1.6 billion since inception and there can be no assurance that we will attain profitability. We had a net loss of $ 389.0 million and net cash used in operations of $ 299.5 million for the year ended December 31, 2022. Cash, cash equivalents, and investments increased to $ 829.3 million as of December 31, 2022 from $ 623.7 million as of December 31, 2021. We anticipate that we will have operating losses and net cash outflows in future periods. We are subject to risks common to late-stage biopharmaceutical companies including, but not limited to, development of new drug candidates, dependence on key personnel, and the ability to obtain additional capital as needed to fund our future plans. Our liquidity will be impaired if sufficient additional capital is not available on terms acceptable to us. To date, we have funded operations primarily through sales of our common stock, contract payments under our collaboration agreements, sales of future revenues and royalties, debt financing arrangements, government grants and interest income. Until we achieve profitable operations, we intend to continue to fund operations through payments from strategic collaborations, additional sales of equity securities, grants and debt financings. We have never generated revenues from commercial sales of our drugs and may not have drugs to market for at least several years, if ever. Our success is dependent on our ability to enter into new strategic collaborations and/or raise additional capital and to successfully develop and market one or more of our drug candidates. We cannot be certain that sufficient funds will be available from such a financing or through a collaborator when required or on satisfactory terms. Additionally, there can be no assurance that our drug candidates will be accepted in the marketplace or that any future products can be developed or manufactured at an acceptable cost. These factors could have a material adverse effect on our future financial results, financial position and cash flows. Based on the current status of our research and development activities, we believe that our existing cash, cash equivalents, and investments will be sufficient to fund cash requirements for at least the next 12 months after the issuance of these consolidated financial statements. If, at any time, our prospects for financing our research and development programs decline, we may decide to reduce research and development expenses by delaying, discontinuing or reducing our funding of one or more of our research or development programs. Alternatively, we might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements do not include any adjustments that might result from the outcome of this uncertainty . |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an ongoing basis. We base our estimates on our historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates. |
Basis of Presentation | Basis of Presentation The consolidated financial statements include the accounts of Cytokinetics, Incorporated and its wholly-owned subsidiaries and have been prepared in accordance with GAAP. Intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform the prior period presentation to the current year. |
Concentration of Credit Risk and Other Risks and Uncertainties | Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject us to concentrations of risk consist principally of cash, cash equivalents, restricted cash equivalents, investments, and accounts receivable. Our cash, cash equivalents, restricted cash equivalents, and investments held with large financial institutions in the United States and deposits may exceed the Federal Deposit Insurance Corporation’s insurance limit. Our exposure to credit risk associated with non-payment includes, but is not limited to, Astellas Pharma Inc. for co-funding one-third of the out-of-pocket clinical development costs which may be incurred in connection with Cytokinetics’ Phase 3 clinical trial, COURAGE-ALS, of reldesemtiv in ALS up to a maximum contribution by Astellas of $ 12.0 million, to our strategic partner in China and Taiwan, Ji Xing , and RPI ICAV, to whom we sold a revenue interest in our net sales of pharmaceutical products containing aficamten under the RP Aficamten RPA, as further described in Note 11 below. Drug candidates we develop may require approvals or clearances from the FDA or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us. |
Cash, Cash Equivalents, and Restricted Cash Equivalents | Cash, Cash Equivalents, and Restricted Cash Equivalents We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents, which consist of money market funds and repurchase agreements backed by U.S. Treasury securities. Repurchase agreements are collateralized by US Treasury securities for an amount not less than 102 % of their value and are reported at a carrying value which approximates fair value due to their short duration. A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in our consolidated balance sheets to the amount reported within our consolidated statements of cash flows was as follows (in thousand): December 31, 2022 2021 Cash and cash equivalents $ 65,582 $ 112,666 Restricted cash equivalents 1,600 — Total cash, cash equivalents, and restricted cash equivalents as reported within our consolidated statement of cash flows $ 67,182 $ 112,666 As of December 31, 2022 , our restricted cash equivalents balance of $ 1.6 million is used to collateralize the letters of credit associated with our fixed and variable rate vehicle allowance and short-term car rental programs. The restricted cash equivalents are classified as other assets based on the remaining term of the underlying restriction. The letters of credit will lapse at the end of the respective contractual terms or upon termination of the arrangement. |
Investments | Investments Available-for-sale investments. Our investments consist of U.S. Treasury securities, U.S. and non-U.S. government agency bonds, commercial paper, global portfolio of corporate debt and money market funds. We designate all investments as available-for-sale and report them at fair value, based on quoted market prices, with unrealized gains and losses recorded in accumulated other comprehensive loss. The cost of securities sold is based on the specific-identification method. Investments with original maturities greater than three months and remaining maturities of one year or less are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. All of our available-for-sale investments are subject to a periodic impairment review. For each available-for-sale investment whose fair value is below its amortized cost, we determine if the impairment is a result of a credit-related loss or other factors using both quantitative and qualitative factors. If the impairment is a result of a credit-related loss, we recognize an allowance for credit losses. If the impairment is not a result of a credit loss, we recognize the loss in other comprehensive loss. |
Property and Equipment, net | Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and are depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three years for computer equipment and software, five years for laboratory equipment and office equipment, and seven years for furniture and fixtures. Amortization of leasehold improvements and finance lease right-of-use assets are computed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, typically ranging from three to twenty-two years . Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. |
Impairment of Long-lived Assets | Impairment of Long-lived Assets We review long-lived assets, including property, equipment and right-of-use assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Impairment is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. We would recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. |
Leases | Leases We determine if the arrangement contains a lease at inception based on whether the contract conveys the right to control the use of an identified asset. The lease classification is determined at lease commencement, which is the date the underlying asset is available for use by the Company, and preliminary based on whether the arrangement is effectively a financed purchase of the underlying asset (finance lease) or not (operating lease). We determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. In addition to the fixed minimum lease payments required under the lease arrangements, certain leases include payments of operating expenses that may be revised based on the landlord’s estimate. These variable payments are excluded from the lease payments used to determine the right-of-use asset and lease liability and are recognized when the associated activity occurs. We recognize right-of-use assets and short-term and long-term lease liabilities on our consolidated balance sheets for operating leases. The right-of-use asset and short-term and long-term lease liabilities for finance leases are recognized in property and equipment, other current liabilities, and other non-current liabilities, respectively, on the consolidated balance sheets. In determining the present value of lease payments, we estimated our incremental borrowing rate based on information available upon commencement. We base the lease liabilities on the present value of remaining lease payments over the remaining terms of the leases using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The initial right-of-use asset, for both operating and finance leases, is measured based on the lease liability adjusted for any initial direct costs, lease prepayments, and lease incentives. We recognize rent expense for operating leases on a straight-line basis over the lease term in operating expenses on the consolidated statements of operations. Finance lease right-of-use assets are amortized on a straight-line basis over the shorter of the expected useful life or the lease term, and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded in interest expense. We exclude from our consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases). We account for lease and non-lease components as a single component for our operating leases. Our operating leases consist of the facilities leases with KR Oyster Point 1, LLC and a facility located in Radnor, Pennsylvania, and our finance leases are for laboratory equipment. |
Revenue Recognition | Revenue Recognition We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration for those goods or services. To recognize revenue from a contract with a customer, we: (i) identify our contracts with our customers; (ii) identify our distinct performance obligations in each contract; (iii) determine the transaction price of each contract; (iv) allocate the transaction price to the performance obligations; and (v) recognize revenue as we satisfy our performance obligations. At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Collaborative Arrangements We enter into collaborative arrangements with partners that typically include payment to us for one of more of the following: (i) license fees; (ii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; (iii) royalties on net sales of licensed products; and (iv) research and development cost reimbursements. Each of these payments results in collaboration or other revenues. Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied. As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The stand-alone selling price may include such items as, forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, to determine the transaction price to allocate to each performance obligation. For our collaboration agreements that include more than one performance obligation, such as a license and/or milestones combined with a commitment to perform research and development services, we make judgments to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate our progress each reporting period and, if necessary, adjust the measure of a performance obligation and related revenue recognition. License Fees : If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Milestone Payments : We use judgment to determine whether a milestone is considered probable of being reached. Using the most likely amount method, we include the value of a milestone payment in the consideration for a contract at inception if we then conclude achieving the milestone is more likely than not. Otherwise, we exclude the value of a milestone payment from contract consideration at inception and recognize revenue for a milestone at a later date, when we judge that it is probable the milestone will be achieved. If we conclude it is probable that a significant revenue reversal would not occur, the associated milestone is included in the transaction price. We then allocate the transaction price to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Royalties : For contracts that include sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. To date, we have not recognized any royalty revenues resulting from contracts. Research and Development Cost Reimbursements : Our joint programs with Astellas under the Astellas OSSA Agreement, and with Amgen under the Amgen Agreement (both of the Astellas OSSA Agreement and the Amgen Agreement having now been terminated), included promises of research and development services. We also entered into the Astellas FSRA Agreement on April 23, 2020. Under the Astellas FSRA Agreement, As tellas agreed to pay one-third of the out-of-pocket clinical development costs which may be incurred in connection with the Company’s Phase 3 clinical trial of reldesemtiv in ALS, up to a maximum contribution by Astellas of $ 12.0 million. We determined that these services collectively were distinct from any licenses provided to Astellas and Amgen under such agreements, and as such, these services were accounted for as a separate performance obligation recorded over time. We recognized revenue for these services as the performance obligations are satisfied, which we estimated using internal research and development costs incurred. |
Accrued Research and Development Expenditures | Accrued Research and Development Expenditures Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. |
Revenue Participation Right Purchase Agreements | Revenue Participation Right Purchase Agreements We have entered into certain revenue participation right purchase agreements with certain investors, pursuant to which such investors purchased rights to royalties from certain revenue streams in exchange for consideration. We typically account for such agreements as debt to be amortized under the effective interest rate method over the life of the related royalty stream, when we have continuing involvement with the underlying R&D. We typically account for such agreements as deferred income to be amortized under the units-of-revenue method, when there is no continuing involvement with the underlying R&D. Revenue participation right purchase agreements are recognized using significant unobservable inputs. These inputs are derived using internal management estimates developed based on third party data and reflect management’s judgements, current market conditions surrounding competing products, and forecasts. We will periodically assess the amount and timing of expected royalty payments and account for any changes in such estimates on a prospective basis . |
Research and Development Expenditures | Research and Development Expenditures Research and development costs are charged to operations as incurred. Research and development expenses consist primarily of clinical manufacturing costs, preclinical study expenses, consulting and other third-party costs, employee compensation, supplies and materials, allocation of overhead and occupancy costs, facilities costs and depreciation of equipment. |
Income Taxes | Income Taxes We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. We recognize uncertain tax positions taken or expected to be taken on a tax return. Tax positions are initially recognized when it is more likely than not that the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is more likely than not of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. We recognize interest accrued related to unrecognized tax benefits and penalties as income tax expense. |
Stock-Based Compensation | Stock-Based Compensation We maintain equity incentive plans under which incentive stock options may be granted to employees and nonqualified stock options, restricted stock awards, performance-based stock units and stock appreciation rights may be granted to employees, directors, consultants and advisors. In addition, we maintain an ESPP under which employees may purchase shares of our common stock through payroll deductions. Stock-based compensation expense related to stock options granted to employees and directors is recognized based on the grant date estimated fair values using the Black Scholes option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. Stock-based compensation expense related to performance-based stock units granted to employees is recognized based on the grant-date fair value of each award and recorded as expense over the vesting period using the ratable method when the underlying performance conditions are deemed probable. Stock-based compensation expense related to the ESPP is recognized based on the fair value of each award estimated on the first day of the offering period using the Black Scholes option pricing model and recorded as expense over the service period using the straight-line method. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06. Under ASU 2020-06 the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument is accounted for as a single liability measured at its amortized cost and convertible preferred stock is accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. We adopted this new guidance using the modified retrospective method as of January 1, 2022, with respect to our 2026 Notes. The cumulative effect of initially applying the new standard was recognized as an adjustment to accumulated deficit. The following table summarizes the adjustments made to our consolidated balance sheet as of January 1, 2022, upon adoption of the new standard (in 000's): Balance sheet account description Ending Balance ASU 2020-06 Adjustments Beginning Balance Convertible notes, net $ 95,471 $ 38,895 $ 134,366 Additional paid-in capital 1,452,268 ( 49,476 ) 1,402,792 Accumulated deficit ( 1,207,620 ) 10,581 ( 1,197,039 ) The adoption of this new guidance resulted in an increase in the carrying value of the 2026 Notes to reflect the full principal amount of the convertible notes outstanding, net of issuance costs, a decrease in additional paid-in capital to remove the equity component separately recorded for the conversion feature associated with the convertible notes, a cumulative-effect adjustment to the beginning balance of our accumulated deficit as of January 1, 2022 to reverse the accretion of discount that resulted from the bifurcation of the equity component of the 2026 Notes, and a reversal of the related deferred tax liability of $ 8.3 million with a corresponding increase in our deferred tax asset valuation allowance. The adoption of this new guidance reduced non-cash interest expense for the year ending December 31, 2022 and will continue to do so until the 2026 Notes have been settled. The remaining debt issuance costs will continue to be amortized over the term of the notes. We have recognized $ 3.6 million of interest expense of the 2026 Notes in 2022 which is $ 3.3 million less than under the previous accounting standards in 2022. Without the adoption of ASU 2020-06, our reported net loss would have increased by $ 3.3 million in 2022. Without the adoption of ASU 2020-06, our reported net loss per share would have increased by $ 0.04 per share in 2022. On July 6, 2022, the Company issued the 2027 Notes and partially repurchased the 2026 Notes as further described in Note 7 – “Debt.” ASU 2020-06 was applied to the 2027 Notes from the moment of issuance, and thus the above adjustments apply only to the 2026 Notes. |
Organization and Accounting P_3
Organization and Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Reconciliation of Cash, Cash Equivalents, and Restricted Cash Equivalents | A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in our consolidated balance sheets to the amount reported within our consolidated statements of cash flows was as follows (in thousand): December 31, 2022 2021 Cash and cash equivalents $ 65,582 $ 112,666 Restricted cash equivalents 1,600 — Total cash, cash equivalents, and restricted cash equivalents as reported within our consolidated statement of cash flows $ 67,182 $ 112,666 |
Summary of Adjustments made to Condensed Consolidated Balance Sheet upon Adoption of New Standard | The following table summarizes the adjustments made to our consolidated balance sheet as of January 1, 2022, upon adoption of the new standard (in 000's): Balance sheet account description Ending Balance ASU 2020-06 Adjustments Beginning Balance Convertible notes, net $ 95,471 $ 38,895 $ 134,366 Additional paid-in capital 1,452,268 ( 49,476 ) 1,402,792 Accumulated deficit ( 1,207,620 ) 10,581 ( 1,197,039 ) |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Earnings Per Share [Abstract] | |
Instruments Excluded from the Computation of Diluted Net Loss Per Share | The following instruments were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been antidilutive (in thousands): Years Ended December 31, 2022 2021 2020 Options to purchase common stock 10,992 9,373 8,510 Warrants to purchase common stock 13 48 48 Restricted stock and performance units 1,260 1,415 1,117 Shares issuable related to the ESPP 13 8 12 Shares issuable upon conversion of 2026 Notes 2,554 16,675 16,675 Shares issuable upon conversion of 2027 Notes 10,572 — — Total shares 25,404 27,519 26,362 |
Research and Development Arra_2
Research and Development Arrangements (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Research and Development [Abstract] | |
Schedule of Allocated Consideration | In December 2021, we entered into the 2021 RTW Transactions with parties that were at the time of our entry into the 2021 RTW Transactions affiliated and in contemplation of one another and, accordingly, we have assessed the accounting for these transactions in the aggregate. Unconstrained arrangement consideration under the 2021 RTW Transactions totaled $70.0 million and was allocated in accordance with ASC 820, Fair Value Measurement, and ASC 606, Revenue from Contracts with Customers, as follows (in thousands): Allocated Units of Accounting: License and collaboration $ 54,856 Common stock (fair value) 15,144 Total consideration $ 70,000 The Company allocated the total consideration in accordance with ASC 820 and ASC 606 as follows (in thousands): Allocated Units of Accounting: License and collaboration (residual) $ 36,501 Royalty (fair value) 87,000 Common stock (fair value) 36,499 Total consideration $ 160,000 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Summary of Fair Value of Financial Assets Consists of Cash Equivalents and Investments Classified as Available-for-sale Securities Measured on Recurring Basis | : December 31, 2022 Fair Value Hierarchy Level Amortized Unrealized Unrealized Fair Money market funds Level 1 $ 45,887 $ — $ — $ 45,887 U.S. Treasury securities Level 1 172,568 — ( 1,102 ) 171,466 U.S. Treasury securities backed repurchase agreements Level 2 16,003 — — 16,003 U.S. and non-U.S. government agency bonds Level 2 136,773 12 ( 889 ) 135,896 Commercial paper Level 2 329,359 28 ( 431 ) 328,956 U.S. and non-U.S. corporate obligations Level 2 128,594 — ( 1,209 ) 127,385 $ 829,184 $ 40 $ ( 3,631 ) $ 825,593 December 31, 2021 Fair Value Hierarchy Level Amortized Unrealized Unrealized Fair Money market funds Level 1 $ 115,937 $ — $ — $ 115,937 U.S. Treasury securities Level 1 133,498 1 ( 268 ) 133,231 U.S. government agency bonds Level 2 33,489 — ( 53 ) 33,436 Commercial paper Level 2 169,622 6 ( 19 ) 169,609 U.S. and non-U.S. corporate obligations Level 2 175,282 — ( 536 ) 174,746 $ 627,828 $ 7 $ ( 876 ) $ 626,959 The available-for-sale securities in our consolidated balance sheet are as follows (in thousands): December 31, 2022 December 31, 2021 Cash equivalents $ 61,890 $ 115,937 Short-term investments 716,995 358,972 Long-term investments 46,708 152,050 $ 825,593 $ 626,959 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Summary of Property and Equipment | Our property and equipment consisted of (in thousands): December 31, 2022 2021 Property and equipment, net: Laboratory equipment $ 18,490 $ 18,837 Computer equipment and software 3,900 4,605 Office equipment, furniture and fixtures 6,056 4,042 Leasehold improvements 65,912 60,343 Construction in progress 741 224 Right-of-use assets, finance lease 2,448 1,409 Total property and equipment 97,547 89,460 Less: Accumulated depreciation ( 17,094 ) ( 16,189 ) $ 80,453 $ 73,271 |
Summary of Accrued Liabilities | Our accrued liabilities were as follows (in thousands): December 31, 2022 2021 Accrued liabilities: Clinical and preclinical costs $ 16,105 $ 13,872 Compensation related 21,767 14,930 Other accrued expenses 6,224 5,568 Total accrued liabilities $ 44,096 $ 34,370 |
Agreements with Royalty Pharma
Agreements with Royalty Pharma (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Agreements with Royalty Pharma [Abstract] | |
Schedule of Total Consideration | The total consideration was allocated as follows (in thousands): Fair Value Proceeds Allocation Units of Accounting: Revenue Participation Right Purchase Agreement $ 69,498 $ 100,000 $ 89,571 Development Funding Loan Agreement 46,887 50,000 60,429 Total consideration $ 116,385 $ 150,000 $ 150,000 |
Schedule of Future Minimum Payments under the Existing Borrowing Under Term Loan Agreement | Future minimum payments under the existing borrowing under RP Loan Agreement are (in thousands): Years ending December 31: 2023 $ 1,440 2024 10,080 2025 11,520 2026 11,520 2027 11,520 Thereafter 48,960 Future minimum payments 95,040 Less: Unamortized interest and loan costs ( 30,272 ) Term Loan, net $ 64,768 |
Schedule of Activity within Liabilities Related to Sale of Future Royalties | Changes to the RP Aficamten Liability and the RP OM Liability are as follows (in thousands) : 2022 2021 RP Aficamten Liability RP OM Liability RP OM Liability Beginning balance, January 1 $ — $ 179,072 $ 166,068 Initial carrying value 89,571 — — Interest accretion 15,546 16,196 12,892 Amortization of issuance costs — 116 112 Ending balance, December 31 $ 105,117 $ 195,384 $ 179,072 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Interest Cost Relating to Notes | The following table presents the total amount of interest cost recognized relating to the 2026 Notes (in thousands): Years Ended December 31, 2022 2021 2020 Contractual interest expense $ 3,265 $ 5,520 $ 5,520 Accretion of debt discount — 5,907 5,246 Accretion of debt issuance costs 355 59 52 Total interest costs recognized $ 3,620 $ 11,486 $ 10,818 The following table presents the total amo unt of interest cost recognized relating to the 2027 Notes (in thousands): 2022 Contractual interest expense $ 9,188 Amortization of debt issuance costs 1,542 Total interest expense recognized $ 10,730 |
Schedule of Maturities of Notes | Future minimum payments under the 2027 Notes and 2026 Notes are (in thousands): Years ending December 31: 2027 Notes 2026 Notes Total 2023 $ 9,450 $ 845 $ 10,295 2024 18,900 845 19,745 2025 18,900 845 19,745 2026 18,900 21,978 40,878 2027 558,900 — 558,900 Future minimum payments 625,050 24,513 649,563 Less: Interest ( 85,050 ) ( 3,381 ) ( 88,431 ) Convertible notes, principal amount 540,000 21,132 561,132 Less: Debt costs on the convertible notes ( 14,871 ) ( 453 ) ( 15,324 ) Net carrying amount of the convertible notes $ 525,129 $ 20,679 $ 545,808 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Equity [Abstract] | |
Summary of Stock Option Activity | Stock option activity in 2022, 2021, and 2020 was as follows: Stock Options Weighted Weighted Aggregate Balance at December 31, 2019 7,759,012 $ 8.59 Granted 1,944,562 15.59 Exercised ( 967,571 ) 8.27 Forfeited ( 234,054 ) 16.06 Balance at December 31, 2020 8,501,949 $ 10.02 Granted 2,513,350 22.43 Exercised ( 1,346,194 ) 9.01 Forfeited ( 296,146 ) 14.56 Balance at December 31, 2021 9,372,959 $ 13.35 Granted 3,424,150 39.79 Exercised ( 1,389,031 ) 10.13 Forfeited ( 415,675 ) 28.94 Balance at December 31, 2022 10,992,403 $ 22.13 7.0 $ 261.9 Exercisable at December 31, 2022 6,153,725 $ 13.21 5.6 $ 200.7 |
Summary of Restricted Stock Unit Activity Including Performance Stock Units | , activity in 2022, 2021, and 2020 was as follows: Number of Weighted Balance at December 31, 2019 839,075 $ 7.49 Granted 731,225 14.40 Exercised ( 435,450 ) 7.72 Forfeited ( 18,208 ) 10.37 Balance at December 31, 2020 1,116,642 $ 11.88 Granted 1,093,450 21.69 Exercised ( 606,240 ) 11.13 Forfeited ( 189,025 ) 21.32 Balance at December 31, 2021 1,414,827 $ 18.52 Granted 780,519 37.69 Exercised ( 707,772 ) 16.72 Forfeited ( 273,310 ) 26.65 Balance at December 31, 2022 1,214,264 $ 30.07 |
Fair Value of Share-Based Payments was Estimated on Date of Grant Based on Assumptions | We use the Black-Scholes option pricing model to determine the fair value of stock option grants to employees and directors and employee stock purchase plan shares. The fair value of share-based payments was estimated on the date of grant based on the following assumptions: Year Ended December Year Ended December Year Ended December Options ESPP Options ESPP Options ESPP Risk-free interest rate 1.41 % to 4.01 % 1.63 % to 4.65 % 0.58 % to 1.28 % 0.05 % 0.42 % to 1.8 % 0.11 % to 1.8 % Volatility 66 % to 67 % 64 % to 65 % 66 % to 67 % 66 % to 67 % 74 % to 75 % 74 % to 75 % Expected term in years 6.3 to 6.4 0.5 6.4 to 6.5 0.5 6.5 to 6.6 0.5 Expected dividend yield 0 % 0 % 0 % 0 % 0 % 0 % |
Summary of Stock-Based Compensation Expense | Stock-based compensation expense for 2022, 2021, and 2020 was as follows (in thousands): Years Ended December 31, 2022 2021 2020 Research and development $ 19,100 $ 10,463 $ 6,949 General and administrative 28,753 16,369 10,671 $ 47,853 $ 26,832 $ 17,620 |
Summary of Outstanding Warrants Issued | As of December 31, 2022, we had the following outstanding warrants issued pursuant to the Term Loan Agreement with a weighted average exercise price of $ 10.42 per share to purchase 12,957 shares of our common stock: Issuance Date Expiration Date Exercise Price Warrants Exercised during Warrants Outstanding at January 2020 January 2030 $ 10.42 8,638 12,957 May 2019 May 2029 9.76 9,226 — August 2018 August 2028 7.10 16,901 — 34,765 12,957 As of December 31, 2021 and 2020, we had the following outstanding warrants issued pursuant to the Term Loan Agreement with a weighted average exercise price of $ 9.12 per share to purchase 47,722 shares of our common stock: o Issuance Date Expiration Date Exercise Price Warrants Outstanding at Warrants Exercised during Warrants Outstanding at January 2020 January 2030 $ 10.42 — — 21,595 May 2019 May 2029 9.76 23,065 13,839 9,226 August 2018 August 2028 7.10 42,253 25,352 16,901 February 2016 February 2026 6.59 51,214 51,214 — October 2015 October 2025 6.90 48,892 48,892 — 165,424 139,297 47,722 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Lease Payments under Non-cancellable Lease | Future minimum lease payments under non-cancellable leases as of December 31, 2022 is as follows (in thousands): Years ending December 31: Operating Leases Finance Leases 2023 $ 13,465 $ 990 2024 18,738 990 2025 19,563 204 2026 20,180 — 2027 20,514 — Thereafter 130,719 — Total future minimum lease payments 223,179 2,184 Less: Imputed interest ( 83,455 ) ( 183 ) Total lease liability $ 139,724 $ 2,001 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Reconciliation of Statutory Federal Income Tax Rate to Effective Tax Rate | The following reconciles the statutory federal income tax rate to our effective tax rate: Years Ended December 31, 2022 2021 2020 Tax at federal statutory tax rate 21 % 21 % 21 % State tax, net of federal benefits 1 % 0 % 1 % Change in state effected rates 0 % ( 1 )% ( 2 )% Tax credits, net 4 % 3 % 3 % Change in valuation allowance ( 26 )% ( 24 )% ( 23 )% Stock-based compensation 2 % 2 % 1 % Other ( 2 )% ( 1 )% ( 1 )% Total 0 % 0 % 0 % |
Summary of Deferred Tax Assets, Net | Deferred tax assets, net, reflecting the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, were as follows (in thousands): As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 202,459 $ 181,977 Tax credits 98,292 77,366 Liability related to sale of future royalties 68,366 38,302 Reserves and accruals 23,950 15,409 Capitalized R&D 48,047 1,115 Long-term lease liability 28,901 26,223 Deferred revenue — 18,608 Total noncurrent deferred tax assets 470,015 359,000 Deferred tax liabilities: Depreciation and amortization ( 7,909 ) ( 7,664 ) Operating lease right-of-use assets ( 18,192 ) ( 15,643 ) Convertible notes — ( 8,296 ) Total noncurrent deferred tax liabilities ( 26,101 ) ( 31,603 ) Less: Valuation allowance ( 443,914 ) ( 327,397 ) Net deferred tax assets $ — $ — |
Schedule of Activity Related to our Gross Unrecognized Tax Benefits | Activity related to our gross unrecognized tax benefits were (in thousands): Years Ended December 31, 2022 2021 2020 Balance at the beginning of the year $ 11,295 $ 10,522 $ 9,922 Increase related to prior year tax positions 4,438 — — Decrease related to prior year tax positions ( 1,804 ) ( 29 ) ( 3 ) Increase related to current year tax positions 4,426 802 603 Balance at the end of the year $ 18,355 $ 11,295 $ 10,522 |
Organization and Accounting P_4
Organization and Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2022 USD ($) Obligation $ / shares | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Jan. 01, 2022 USD ($) | |
Summary Of Significant Accounting Policies [Line Items] | ||||
Accumulated deficit incurred | $ (1,585,994) | $ (1,207,620) | $ (1,197,039) | |
Net loss | (388,955) | (215,314) | $ (127,290) | |
Net cash provided by (used in) operating activities | 299,516 | 142,522 | (8,943) | |
Cash, cash equivalents and investments | $ 829,300 | 623,700 | ||
Cash requirements term | 12 months | |||
Interest expense | $ 19,414 | $ 16,440 | $ 15,963 | |
Restricted cash equivalents | 1,600 | |||
ASU 2020-06 [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Accumulated deficit incurred | 10,581 | |||
Deferred tax liability reversal | $ 8,300 | |||
Increase in net loss | $ 3,300 | |||
Increase in net loss per share | $ / shares | $ 0.04 | |||
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] | true | |||
ASU 2020-06 [Member] | 2026 Notes [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Interest expense | $ 3,600 | |||
Decrease in interest expense | $ 3,300 | |||
Minimum [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Number of performance obligation | Obligation | 1 | |||
Maximum [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Percentage of securities collateralized value | 102% | |||
Computer Equipment and Software [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Property and equipment estimated useful lives | 3 years | |||
Laboratory Equipment and Office Equipment [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Property and equipment estimated useful lives | 5 years | |||
Furniture and Fixtures [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Property and equipment estimated useful lives | 7 years | |||
Leasehold Improvements [Member] | Minimum [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Property and equipment estimated useful lives | 3 years | |||
Leasehold Improvements [Member] | Maximum [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Property and equipment estimated useful lives | 22 years | |||
Astellas [Member] | Astellas FSRA Agreement [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Payment of development costs for clinical trials of reldesemtiv | $ 12,000 |
Organization and Accounting P_5
Organization and Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash Equivalents (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Cash and cash equivalents | $ 65,582 | $ 112,666 |
Restricted cash equivalents | 1,600 | |
Total cash, cash equivalents, and restricted cash equivalents as reported within our consolidated statement of cash flows | $ 67,182 | $ 112,666 |
Organization and Accounting P_6
Organization and Accounting Policies - Summary of Adjustments made to Condensed Consolidated Balance Sheet upon Adoption of New Standard (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Jan. 01, 2022 | Dec. 31, 2021 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Convertible notes, net | $ 134,366 | $ 95,471 | |
Additional paid-in capital | 1,402,792 | 1,452,268 | |
Accumulated deficit | $ (1,585,994) | (1,197,039) | $ (1,207,620) |
ASU 2020-06 [Member] | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Convertible notes, net | 38,895 | ||
Additional paid-in capital | (49,476) | ||
Accumulated deficit | $ 10,581 |
Net Loss Per Share - Instrument
Net Loss Per Share - Instruments Excluded from the Computation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 25,404 | 27,519 | 26,362 |
Options to Purchase Common Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 10,992 | 9,373 | 8,510 |
Warrants to Purchase Common Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 13 | 48 | 48 |
Restricted Stock and Performance Units [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 1,260 | 1,415 | 1,117 |
Shares Issuable Related to the ESSP [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 13 | 8 | 12 |
2026 Notes [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 2,554 | 16,675 | 16,675 |
2027 Notes [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Total shares | 10,572 | 0 | 0 |
Research and Development Arra_3
Research and Development Arrangements - Schedule of Allocated Consideration (Detail) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | |||
Jul. 14, 2020 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Total revenues | $ 94,588 | $ 70,428 | $ 55,828 | ||
RTW [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Total consideration | $ 70,000 | ||||
RTW [Member] | Collaborative Arrangement [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Total consideration | $ 160,000 | ||||
RTW [Member] | Common Stock [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Fair value of common stock | 15,144 | ||||
RTW [Member] | Common Stock [Member] | Collaborative Arrangement [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Fair value of common stock | 36,499 | ||||
RTW [Member] | License and Collaboration [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Total revenues | $ 54,856 | ||||
RTW [Member] | License and Collaboration [Member] | Collaborative Arrangement [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Total revenues | 36,501 | ||||
RTW [Member] | Royalty [Member] | Collaborative Arrangement [Member] | |||||
Allocated Transaction Prices Of Collaborative Arrangements [Line Items] | |||||
Fair Value of Royalty | $ 87,000 |
Research and Development Arra_4
Research and Development Arrangements - Additional Information (Detail) - USD ($) | 3 Months Ended | 12 Months Ended | |||||||
Apr. 25, 2022 | Dec. 20, 2021 | Jul. 14, 2020 | Apr. 23, 2020 | Sep. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2022 | |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | $ 94,588,000 | $ 70,428,000 | $ 55,828,000 | ||||||
Accounts receivable | 147,000 | 51,819,000 | |||||||
Amount received as milestone payment | $ 5,000,000 | ||||||||
Long-term deferred revenue | 0 | 87,000,000 | |||||||
Ji Xing Omecamtiv Mecarbil License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Nonrefundable payment obligation | $ 50,000,000 | ||||||||
Amount received as milestone payment | $ 50,000,000 | ||||||||
Ji Xing Aficamten License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Upfront payment received | $ 25,000,000 | ||||||||
Royalty Purchase Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | $ 87,000,000 | ||||||||
Sale of interest in future royalties | $ 85,000,000 | ||||||||
Fair Value of Royalty | 87,000,000 | ||||||||
Long-term deferred revenue | $ 87,000,000 | ||||||||
Common Stock Purchase Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Issuance of common stock upon private placement, shares | 511,182 | 2,000,000 | |||||||
Shares Issued, price per share | $ 39.125 | $ 25 | |||||||
Net proceeds of issuance of common stock | $ 20,000,000 | $ 50,000,000 | |||||||
Common stock purchase agreement date | Dec. 20, 2021 | Jul. 14, 2020 | |||||||
Excess amount paid over the fair value of the shares | $ 4,900,000 | $ 13,500,000 | |||||||
Fair value of common stock | 15,100,000 | 36,500,000 | |||||||
Maximum [Member] | Ji Xing Omecamtiv Mecarbil License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Potential additional payments receivable | 330,000,000 | ||||||||
Maximum [Member] | Ji Xing Aficamten License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Potential additional payments receivable | 200,000,000 | ||||||||
Maximum [Member] | Funding Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Potential milestone receivable | $ 90,000,000 | ||||||||
2016 Astellas Amendment [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Reimbursement of clinical development costs | 9,300,000 | ||||||||
2016 Astellas Amendment [Member] | Maximum [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Payment of development costs for clinical trials of reldesemtiv | $ 12,000,000 | ||||||||
Rights Granted [Member] | Ji Xing Omecamtiv Mecarbil License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Nonrefundable payment obligation | 40,000,000 | ||||||||
New Drug Application [Member] | Ji Xing Omecamtiv Mecarbil License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Nonrefundable payment obligation | $ 10,000,000 | ||||||||
License Revenues [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | 0 | 54,856,000 | 36,501,000 | ||||||
License Revenues [Member] | Ji Xing Aficamten License and Collaboration Agreement [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | 0 | 36,500,000 | |||||||
Research and Development Revenues [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | 6,588,000 | 10,572,000 | 16,527,000 | ||||||
Amgen | Research And Development Milestone Grant And Other Revenues Net | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | 0 | 7,400,000 | 10,000,000 | ||||||
Astellas [Member] | Accounting Standards Update 2014-09 | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Accounts receivable | 0 | 1,800,000 | |||||||
Astellas [Member] | Research and Development Revenues [Member] | |||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||||||
Total revenues | $ 5,700,000 | $ 3,200,000 | $ 6,600,000 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Fair Value of Financial Assets Consists of Cash Equivalents and Investments Classified as Available-for-sale Securities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair Value | $ 825,593 | $ 626,959 |
Long-term Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair Value | 46,708 | 152,050 |
Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 829,184 | 627,828 |
Unrealized Gains | 40 | 7 |
Unrealized Losses | (3,631) | (876) |
Fair Value | 825,593 | 626,959 |
Money Market Funds [Member] | Fair Value Measurements Using Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 45,887 | 115,937 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | 0 |
Fair Value | 45,887 | 115,937 |
U.S. Treasury Securities [Member] | Fair Value Measurements Using Level 1 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 172,568 | 133,498 |
Unrealized Gains | 0 | 1 |
Unrealized Losses | (1,102) | (268) |
Fair Value | 171,466 | 133,231 |
U.S. Treasury securities backed repurchase agreements [Member] | Fair Value Measurements Using Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 16,003 | |
Unrealized Gains | 0 | |
Unrealized Losses | 0 | |
Fair Value | 16,003 | |
U.S. and Non-U.S. Government Agency Bonds [Member] | Fair Value Measurements Using Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 136,773 | |
Unrealized Gains | 12 | |
Unrealized Losses | (889) | |
Fair Value | 135,896 | |
U.S. Government Agency Bonds [Member] | Fair Value Measurements Using Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 33,489 | |
Unrealized Gains | 0 | |
Unrealized Losses | (53) | |
Fair Value | 33,436 | |
Commercial Paper [Member] | Fair Value Measurements Using Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 329,359 | 169,622 |
Unrealized Gains | 28 | 6 |
Unrealized Losses | (431) | (19) |
Fair Value | 328,956 | 169,609 |
U.S. and Non-U.S. Corporate Obligations [Member] | Fair Value Measurements Using Level 2 [Member] | Fair Value, Measurements, Recurring [Member] | Cash and Cash Equivalents and Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 128,594 | 175,282 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | (1,209) | (536) |
Fair Value | 127,385 | 174,746 |
Cash Equivalents [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair Value | 61,890 | 115,937 |
Short-term Investments [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Fair Value | $ 716,995 | $ 358,972 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |||
Interest Income | $ 11,400,000 | $ 1,000,000 | $ 5,300,000 |
Credit losses on debt securities | $ 0 | $ 0 |
Balance Sheet Components - Summ
Balance Sheet Components - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 97,547 | $ 89,460 |
Less: Accumulated depreciation | (17,094) | (16,189) |
Total property and equipment, net | 80,453 | 73,271 |
Laboratory Equipment [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 18,490 | 18,837 |
Computer Equipment and Software [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 3,900 | 4,605 |
Office Equipment, Furniture and Fixtures [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 6,056 | 4,042 |
Leasehold Improvements [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 65,912 | 60,343 |
Construction in Progress [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | 741 | 224 |
Right-of-Use Assets, Finance Lease [Member] | ||
Property Plant And Equipment [Line Items] | ||
Total property and equipment | $ 2,448 | $ 1,409 |
Balance Sheet Components - Addi
Balance Sheet Components - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |||
Depreciation expense | $ 5.8 | $ 2.3 | $ 1.8 |
Employer contributions under the plan | $ 1.8 | $ 1.1 | $ 0.9 |
Balance Sheet Components - Su_2
Balance Sheet Components - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Accrued liabilities: | ||
Clinical and preclinical costs | $ 16,105 | $ 13,872 |
Compensation related | 21,767 | 14,930 |
Other accrued expenses | 6,224 | 5,568 |
Total accrued liabilities | $ 44,096 | $ 34,370 |
Agreements with Royalty Pharm_2
Agreements with Royalty Pharma - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | ||||||
Jan. 07, 2022 | Feb. 28, 2017 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Jul. 01, 2023 | Mar. 31, 2023 | Jun. 30, 2022 | |
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Arrangement consideration of debt transaction | $ 150,000 | |||||||
Long term debt | $ 649,563 | |||||||
Debt Instrument, Face Amount | 561,132 | |||||||
Interest expense | $ 19,414 | $ 16,440 | $ 15,963 | |||||
Purchase of common stock shares | 94,833,975 | 84,799,542 | ||||||
Liabilities | $ 1,122,675 | $ 597,456 | ||||||
RP Aficamten RPA, RPI ICAV [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Liabilities related to revenue participation right purchase agreements, net | 195,400 | |||||||
RP Loan Agreement [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Long term debt | 64,768 | |||||||
RPI Finance Trust [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Liabilities related to revenue participation right purchase agreements, net | 105,100 | |||||||
RP Aficamten RPA and RP OM RPA [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Non-cash interest expense recognized | $ 31,700 | $ 12,900 | ||||||
R P O M R P A [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Non-cash interest expense recognized | 22,700 | |||||||
2022 Royalty Pharma Transactions [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Milestone payment | 50,000 | |||||||
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Upfront payment | 50,000 | |||||||
Purchased rights to certain revenue streams from net sales in consideration payment | $ 50,000 | |||||||
Percentage of net sales payable | 4.50% | |||||||
4.5% of net revenue to be receivable from annual worldwide net sales | $ 1,000,000 | |||||||
Percentage of net sales payable for excess of annual worldwide net sales | 3.50% | |||||||
3.5% of net sales payable for excess of annual worldwide net sales | $ 1,000,000 | |||||||
Imputed rate of interest on unamortized portion of liability | 22.40% | |||||||
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member] | oHCM [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Amount payable of first pivotal clinical trail | 50,000 | |||||||
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member] | nHCM [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Amount payable of first pivotal clinical trail | 50,000 | |||||||
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member] | Maximum [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Purchased rights to certain revenue streams from net sales in consideration payment | $ 150,000 | |||||||
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member] | Change in Accounting Estimate [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Imputed rate of interest on unamortized liability | 22.40% | 11.70% | ||||||
Increase (reduction) in net loss | $ 5,300 | |||||||
Increase (reduction) in net loss per share | $ 0.06 | |||||||
2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Long term debt | $ 64,800 | |||||||
Term loan, maturity year | 10 years | |||||||
Debt instrument effective interest rate | 7.65% | |||||||
Applicable prepayment charges on term loan | $ 34,600 | |||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||
Interest expense | 4,800 | |||||||
2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | Term Loan Tranche 1, Tranche 4 and Tranche 5 [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Repayable loan percentage to principal amount Including interest and other fees | 190% | |||||||
2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | Term Loan Tranche 2 and Tranche 3 [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Repayable loan percentage to principal amount Including interest and other fees | 200% | |||||||
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA [Member] | Change in Accounting Estimate [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Non-cash interest expense recognized | $ 15,500 | |||||||
Royalty Purchase Finance Trust Agreement [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Imputed rate of interest on unamortized liability | 8.50% | 10% | ||||||
Liabilities related to revenue participation right purchase agreements, net | $ 195,384 | $ 179,072 | $ 166,068 | |||||
Royalty Purchase Finance Trust Agreement [Member] | Change in Accounting Estimate [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Imputed rate of interest on unamortized liability | 8.50% | 10% | ||||||
Non-cash interest expense recognized | $ 16,200 | $ 12,900 | ||||||
Increase (reduction) in net loss | $ (1,800) | |||||||
Increase (reduction) in net loss per share | $ (0.02) | |||||||
CRL Option [Member] | 2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Term loan, maximum borrowing capacity | $ 300,000 | |||||||
Term loan, current borrowing capacity | 50,000 | |||||||
Term loan, remaining borrowing capacity | 250,000 | |||||||
CRL Option [Member] | 2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | Term Loan Tranche 2 [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Long term debt | 50,000 | |||||||
CRL Option [Member] | 2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | Term Loan Tranche 3 [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Long term debt | 25,000 | |||||||
CRL Option [Member] | 2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | Term Loan Tranche 4 [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Long term debt | 75,000 | |||||||
CRL Option [Member] | 2022 Royalty Pharma Transactions [Member] | RP Loan Agreement [Member] | Term Loan Tranche 5 [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Long term debt | $ 100,000 | |||||||
CRL Option [Member] | Royalty Purchase Finance Trust Agreement [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Cash payment under royalty agreement | $ 90,000 | |||||||
Purchase of common stock shares | 875,656 | |||||||
Stock issued during period, value, issued for services | $ 10,000 | |||||||
Liabilities | $ 92,300 | |||||||
Additional percent of royalty on net sale | 1% | |||||||
CRL Option [Member] | Royalty Purchase Finance Trust Agreement [Member] | Minimum [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Percent of royalty on net sale | 5.50% | 4.50% | ||||||
CRL Option [Member] | Royalty Purchase Finance Trust Agreement [Member] | Forecast [Member] | Maximum [Member] | ||||||||
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] | ||||||||
Increase in royalty rate | 5.50% | 5.50% |
Agreements with Royalty Pharm_3
Agreements with Royalty Pharma - Schedule of Total Consideration (Detail) - 2022 Royalty Pharma Transactions [Member] $ in Thousands | Jan. 07, 2022 USD ($) |
Debt Instrument [Line Items] | |
Consideration Fair Value | $ 116,385 |
Consideration proceeds | 150,000 |
Consideration allocation | 150,000 |
Revenue Participation Right Purchase Agreements | |
Debt Instrument [Line Items] | |
Consideration Fair Value | 69,498 |
Consideration proceeds | 100,000 |
Consideration allocation | 89,571 |
Development Funding Loan Agreement | |
Debt Instrument [Line Items] | |
Consideration Fair Value | 46,887 |
Consideration proceeds | 50,000 |
Consideration allocation | $ 60,429 |
Agreements with Royalty Pharm_4
Agreements with Royalty Pharma - Schedule of Future Minimum Payments under Term Loan Agreement (Detail) $ in Thousands | Dec. 31, 2022 USD ($) |
Debt Instrument [Line Items] | |
2023 | $ 10,295 |
2024 | 19,745 |
2025 | 19,745 |
2026 | 40,878 |
2027 | 558,900 |
Less: Unamortized interest and loan costs | (15,324) |
Term Loan, net | 649,563 |
RP Loan Agreement [Member] | |
Debt Instrument [Line Items] | |
2023 | 1,440 |
2024 | 10,080 |
2025 | 11,520 |
2026 | 11,520 |
2027 | 11,520 |
Thereafter | 48,960 |
Future minimum payments | 95,040 |
Less: Unamortized interest and loan costs | (30,272) |
Term Loan, net | $ 64,768 |
Agreements with Royalty Pharm_5
Agreements with Royalty Pharma - Schedule Represents Allocation of Transaction Consideration on a Relative Fair Value Basis to the Liability and the Common Stock (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
RP Aficamten Liability | ||
Royalty Liability [Line Items] | ||
Liabilities related to revenue participation right purchase agreements, net beginning balance | $ 0 | |
Initial carrying value | 89,571 | |
Interest accretion | 15,546 | |
Amortization of issuance costs | 0 | |
Liabilities related to revenue participation right purchase agreements, net ending balance | 105,117 | $ 0 |
RPOM Liability | ||
Royalty Liability [Line Items] | ||
Liabilities related to revenue participation right purchase agreements, net beginning balance | 179,072 | 166,068 |
Initial carrying value | 0 | 0 |
Interest accretion | 16,196 | 12,892 |
Amortization of issuance costs | 116 | 112 |
Liabilities related to revenue participation right purchase agreements, net ending balance | $ 195,384 | $ 179,072 |
Debt - Additional Information (
Debt - Additional Information (Detail) | 12 Months Ended | ||||||
Oct. 24, 2022 USD ($) | Jul. 06, 2022 USD ($) $ / shares shares | Nov. 13, 2019 USD ($) $ / shares shares | Nov. 07, 2019 $ / shares | Dec. 31, 2022 USD ($) Days $ / shares shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2020 USD ($) | |
Debt Instrument [Line Items] | |||||||
Principal amount of original loan | $ 561,132,000 | ||||||
Loss on extinguishment of debt | 2,693,000 | $ 0 | $ 0 | ||||
Convertible notes, principal amount | 561,132,000 | ||||||
Interest expense | $ 19,414,000 | $ 16,440,000 | 15,963,000 | ||||
Common stock, par value | $ / shares | $ 0.001 | $ 0.001 | |||||
Conversion of units | $ 484,400,000 | ||||||
Cash Settlement of capped call options associated with 2026 Notes | (26,392,000) | $ 0 | 0 | ||||
Cap price of capped call transactions | $ / shares | $ 14.07 | ||||||
Capped call premium percentage of sale price of common stock | 70% | ||||||
Proceeds from Convertible Debt | 523,586,000 | 0 | 0 | ||||
Oxford and Silicon Valley Bank [Member] | Term Loan Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Loss on extinguishment of debt | $ (2,700,000) | ||||||
Oxford and Silicon Valley Bank [Member] | 2019 Term Loan [Member] | Term Loan Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Interest expense | $ 4,800,000 | $ 4,900,000 | |||||
Oxford and Silicon Valley Bank [Member] | 2019 Term Loan [Member] | Amended Loan Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument, applicable interest rate for scenario 1 | 8.05% | ||||||
Debt instrument, base interest rate for scenario 2 | 6.81% | ||||||
Interest rate description | Both borrowings under the Term Loan Agreement were subject to interest at an annual rate equal to the greater of (a) 8.05% or (b) the sum of 6.81% plus the 30-day U.S. LIBOR rate. | ||||||
Oxford and Silicon Valley Bank [Member] | 2019 Term Loan [Member] | New Loan and Security Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Loan repayment terms | The borrowing under the Term Loan Agreement was repayable in monthly interest-only payments through December 31, 2020. The interest-only period was automatically extended until July 1, 2021 as a result of the Company’s initiation of a Phase 2 trial for aficamten in oHCM and was extended through December 31, 2021 as a result of the achievement of positive results in GALACTIC-HF, the trial of omecamtiv mecarbil in chronic heart failure as announced on October 8, 2020. The ultimate interest-only period was to be followed by equal monthly payments of principal and interest to the maturity date in December 2023. | ||||||
Final payment fee percentage | 6% | ||||||
2026 Notes [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Principal amount of original loan | $ 138,000,000 | $ 21,132,000 | |||||
Underwritten public offering of common stock, net of discounts, commissions and offering cost, shares | shares | 8,071,343 | ||||||
Repurchase of principal amount of original loan | $ 116,900,000 | ||||||
Inducement loss as a result of partial repurchase | 22,200,000 | ||||||
Debt Instrument, Frequency of Periodic Payment | payable semi-annually on May 15 and December 15 of each year, beginning May 15, 2020 | ||||||
Number of instalments description | payable semi-annually on May 15 and December 15 of each year, beginning May 15, 2020 | ||||||
Convertible notes, principal amount | $ 138,000,000 | $ 21,132,000 | |||||
Convertible notes, interest rate | 4% | ||||||
Convertible debt, fair value | $ 94,800,000 | ||||||
Convertible notes, maturity date | Nov. 15, 2026 | ||||||
Convertible notes, sinking fund | $ 0 | ||||||
Convertible notes, shares issued | shares | 94.7811 | ||||||
Convertible notes, principal amount | $ 1,000 | ||||||
Convertible notes, initial conversion price | $ / shares | $ 10.55 | ||||||
Convertible notes, type of equity security issued | common stock | ||||||
Net proceeds from convertible notes, net of debt discount and issuance costs | $ 133,900,000 | ||||||
Convertible notes, conversion description | The 2026 Notes may be converted at the option of the holder under any of the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter exceeds 127.5% of the last reported sale price of the Company’s common stock on November 7, 2019; (2) during the 5 consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) if the trading price per $1,000 principal amount of 2026 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company’s common stock; (4) if the Company calls the 2026 Notes for redemption; and (5) at any time from, and including, July 15, 2026 until the close of business on the scheduled trading day immediately before the maturity date, November 15, 2026. The Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate. The 2026 Notes are convertible at December 31, 2022 based on circumstance (1) defined above. | ||||||
Aggregate principal amount remaining | $ 21,100,000 | ||||||
Convertible notes, redemption description | The 2026 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after November 20, 2023 and, in the case of any partial redemption, on or before the 60th scheduled trading day before the maturity date, at a cash redemption price equal to the principal amount of the 2026 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. If a “fundamental change” (as defined in the indenture agreement, dated November 13, 2019 between the Company and U.S. Bank National Association, as trustee, as supplemented by the first supplemental indenture dated as of November 13, 2019 between the Company and such trustee) occurs, then, subject to certain exceptions, holders may require the Company to repurchase their 2026 Notes at a cash repurchase price equal to the principal amount of the 2026 Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. | ||||||
Debt instrument, unamortized debt issuance cost | $ 500,000 | ||||||
Unamortized debt discount amortization period | 3 years 10 months 24 days | ||||||
Conversion of units | shares | 2,600,000 | ||||||
Conversion of units | $ 117,000,000 | ||||||
Stock price | $ / shares | $ 45.82 | ||||||
If-converted value in excess of principal amount | $ 95,900,000 | ||||||
Cash Settlement of capped call options associated with 2026 Notes | $ 13,400,000 | ||||||
Proceeds from termination of capped call options associated with convertible notes | $ 26,400,000 | ||||||
2026 Notes [Member] | Liability [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument effective interest rate | 4.60% | ||||||
2026 Notes [Member] | Debt Instrument Convertible Covenant One [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Convertible notes, percentage of conversion price | 127.50% | ||||||
Convertible notes, trading days | Days | 20 | ||||||
Convertible notes, consecutive trading days | Days | 30 | ||||||
2026 Notes [Member] | Debt Instrument Convertible Covenant Two [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Convertible notes, percentage of last reported sale price of common stock | 98% | ||||||
Convertible notes, trading days | Days | 5 | ||||||
Convertible notes, consecutive trading days | Days | 10 | ||||||
2027 Notes [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Principal amount of original loan | $ 540,000,000 | $ 540,000,000 | |||||
Debt Instrument, Frequency of Periodic Payment | payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2023 | ||||||
Payment associated with convertible notes | $ 140,300,000 | ||||||
Number of instalments description | payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2023 | ||||||
Convertible notes, principal amount | $ 540,000,000 | 540,000,000 | |||||
Convertible notes, interest rate | 3.50% | ||||||
Convertible debt, fair value | 620,300,000 | ||||||
Convertible notes, maturity date | Jul. 01, 2027 | ||||||
Convertible notes, shares issued | shares | 19.5783 | ||||||
Convertible notes, principal amount | $ 1,000 | $ 1,000 | |||||
Convertible notes, initial conversion price | $ / shares | $ 51.08 | ||||||
Convertible notes, type of equity security issued | Common Stock | ||||||
Net proceeds from convertible notes, net of debt discount and issuance costs | $ 523,600,000 | ||||||
Convertible notes, conversion description | The 2027 Notes are convertible into cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, based on the applicable conversion rate(s). The initial conversion rate for the 2027 Notes is 19.5783 shares of the Company’s Common Stock per $1,000 principal amount of such Notes, which is equivalent to an initial conversion price of approximately $51.08 per share. Holders of the 2027 Notes may convert all or any portion of their convertible notes at their option only in the following circumstances: (i) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2022, if the last reported sale price per share of the Company’s common stock, $0.001 par value per share, exceeds 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (ii) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) if the trading price per $1,000 principal amount of 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (iii) upon the occurrence of certain corporate events or distributions on the Company’s common stock, as described in the 2027 Indenture; (iv) if the Company calls such 2027 Notes for redemption; and (v) at any time from, and including, March 1, 2027 until the close of business on the scheduled trading day immediately before the maturity date. | ||||||
Convertible notes, redemption description | The Company may not redeem the 2027 Notes at its option at any time before July 7, 2025. The 2027 Notes will be redeemable, in whole or in part (subject to the “Partial Redemption Limitation” (as defined in the 2027 Indenture)), at the Company’s option at any time, and from time to time, on or after July 7, 2025 and, in the case of a partial redemption, on or before the 60th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the 2027 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any of the 2027 Notes for redemption will constitute a Make-Whole Fundamental Change with respect to that convertible note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. The conversion rate for the 2027 Notes shall not exceed 25.4517 shares per $1,000 principal amount of such Notes, subject to certain customary anti-dilution adjustments (as defined in the 2027 indenture). Pursuant to the Partial Redemption Limitation, the Company may not elect to redeem less than all of the outstanding 2027 Notes unless at least $75.0 million aggregate principal amount of 2027 Notes are outstanding and not subject to redemption as of the time the Company sends the related redemption notice. | ||||||
Notes issuance costs | $ 16,400,000 | ||||||
Notes issuance costs amortization period | 5 years | ||||||
Debt instrument, unamortized debt issuance cost | $ 14,900,000 | ||||||
Unamortized debt discount amortization period | 4 years 7 months 6 days | ||||||
Conversion of units | shares | 10,500,000 | ||||||
Stock price | $ / shares | $ 45.82 | ||||||
If-converted value in excess of principal amount | $ 540,000,000 | ||||||
2027 Notes [Member] | Liability [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument effective interest rate | 4.17% | ||||||
2027 Notes [Member] | Debt Instrument Convertible Covenant One [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Convertible notes, percentage of conversion price | 130% | ||||||
Convertible notes, trading days | Days | 20 | ||||||
Convertible notes, consecutive trading days | Days | 30 | ||||||
Common stock, par value | $ / shares | $ 0.001 | ||||||
2027 Notes [Member] | Debt Instrument Convertible Covenant Two [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Convertible notes, percentage of last reported sale price of common stock | 98% | ||||||
Convertible notes, trading days | Days | 5 | ||||||
Convertible notes, consecutive trading days | Days | 10 | ||||||
2027 Notes [Member] | Maximum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Convertible notes, shares issued | shares | 25.4517 | ||||||
2027 Notes [Member] | Minimum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Aggregate principal amount of notes outstanding | $ 75,000,000 |
Debt - Schedule of Interest Cos
Debt - Schedule of Interest Cost Relating to 2026 and 2027 Notes (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
2026 Notes [Member] | |||
Debt Instrument [Line Items] | |||
Contractual interest expense | $ 3,265 | $ 5,520 | $ 5,520 |
Accretion of debt discount | 0 | 5,907 | 5,246 |
Accretion of debt issuance costs | 355 | 59 | 52 |
Total interest expense recognized | 3,620 | $ 11,486 | $ 10,818 |
2027 Notes [Member] | |||
Debt Instrument [Line Items] | |||
Contractual interest expense | 9,188 | ||
Amortization of debt issuance costs | 1,542 | ||
Total interest expense recognized | $ 10,730 |
Debt - Schedule of Future Minim
Debt - Schedule of Future Minimum Payments under 2026 Notes (Detail) - USD ($) | Dec. 31, 2022 | Jul. 06, 2022 | Dec. 31, 2021 | Nov. 13, 2019 |
Debt Instrument [Line Items] | ||||
2023 | $ 10,295,000 | |||
2024 | 19,745,000 | |||
2025 | 19,745,000 | |||
2026 | 40,878,000 | |||
2027 | 558,900,000 | |||
Term Loan, net | 649,563,000 | |||
Less: Interest | (88,431,000) | |||
Debt Instrument, Face Amount, Total | 561,132,000 | |||
Less: Debt costs on the convertible notes | (15,324,000) | |||
Net carrying amount of the convertible notes | 545,808,000 | $ 95,471,000 | ||
2027 Notes [Member] | ||||
Debt Instrument [Line Items] | ||||
2023 | 9,450,000 | |||
2024 | 18,900,000 | |||
2025 | 18,900,000 | |||
2026 | 18,900,000 | |||
2027 | 558,900,000 | |||
Term Loan, net | 625,050,000 | |||
Less: Interest | (85,050,000) | |||
Debt Instrument, Face Amount, Total | 540,000,000 | $ 540,000,000 | ||
Less: Debt costs on the convertible notes | (14,871,000) | |||
Net carrying amount of the convertible notes | 525,129,000 | |||
2026 Notes [Member] | ||||
Debt Instrument [Line Items] | ||||
2023 | 845,000 | |||
2024 | 845,000 | |||
2025 | 845,000 | |||
2026 | 21,978,000 | |||
2027 | 0 | |||
Term Loan, net | 24,513,000 | |||
Less: Interest | (3,381,000) | |||
Debt Instrument, Face Amount, Total | 21,132,000 | $ 138,000,000 | ||
Less: Debt costs on the convertible notes | (453,000) | |||
Net carrying amount of the convertible notes | $ 20,679,000 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
May 31, 2022 $ / shares shares | Jun. 30, 2022 $ / shares shares | May 31, 2021 Tranche $ / shares shares | May 31, 2020 shares | Mar. 31, 2020 USD ($) | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 31, 2019 shares | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Intrinsic value of stock options outstanding | $ | $ 261,900,000 | ||||||||
Allocated share based compensation expense | $ | 47,853,000 | $ 26,832,000 | $ 17,620,000 | ||||||
Claims settlement | $ | $ 2,200,000 | $ 0 | $ 0 | $ 2,151,000 | |||||
Common Stock [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Issuance of common stock pursuant to ESPP, shares | 98,153 | 108,780 | 134,684 | ||||||
Oxford and Silicon Valley Bank [Member] | New Loan and Security Agreement [Member] | 2019 Term Loan [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Outstanding warrants | 12,957 | 47,722 | 47,722 | 165,424 | |||||
Warrants exercised, weighted average exercise price | $ / shares | $ 10.42 | $ 9.12 | $ 9.12 | ||||||
Warrants exercised | 34,765 | 139,297 | |||||||
Oxford and Silicon Valley Bank [Member] | New Loan and Security Agreement [Member] | 2019 Term Loan [Member] | Common Stock [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Outstanding warrants | 28,306 | ||||||||
Oxford and Silicon Valley Bank [Member] | New Loan and Security Agreement [Member] | 2019 Term Loan [Member] | Warrants exercised in May 2022 [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Warrants exercise price | $ / shares | $ 7.10 | ||||||||
Warrants exercised | 16,901 | ||||||||
Oxford and Silicon Valley Bank [Member] | New Loan and Security Agreement [Member] | 2019 Term Loan [Member] | Warrants exercised in June 2022 [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Warrants exercise price | $ / shares | $ 9.76 | ||||||||
Warrants exercised | 9,226 | ||||||||
Oxford and Silicon Valley Bank [Member] | New Loan and Security Agreement [Member] | 2019 Term Loan [Member] | Warrants exercised in June 2022 [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Warrants exercise price | $ / shares | $ 10.42 | ||||||||
Warrants exercised | 8,638 | ||||||||
Restricted Stock Units (RSUs) | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Share based compensation, vested restricted stock units, total fair value | $ | $ 26,200,000 | ||||||||
Unamortized/unrecognized stock-based compensation expense | $ | $ 20,500,000 | ||||||||
Weighted-average period | 1 year 6 months | ||||||||
Restricted Stock Units (RSUs) | Minimum [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Vesting period | 2 years | ||||||||
Restricted Stock Units (RSUs) | Maximum [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Vesting period | 3 years | ||||||||
Performance Stock Units | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Shares available for grant | 375,000 | ||||||||
Per unit weighted average grant date fair value | $ / shares | $ 25.32 | ||||||||
Number of tranche | Tranche | 2 | ||||||||
Performance Stock Units | Tranche One | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Share-based compensation arrangement by share based payment award award vesting rights percentage | 50% | ||||||||
Allocated share based compensation expense | $ | $ 700,000 | ||||||||
Unamortized/unrecognized stock-based compensation expense | $ | $ 100,000 | ||||||||
Performance Stock Units | Tranche Two | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Share-based compensation arrangement by share based payment award award vesting rights percentage | 50% | ||||||||
Number of shares cancelled | 182,500 | ||||||||
Allocated share based compensation expense | $ | $ 0 | ||||||||
Options [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Unamortized/unrecognized stock-based compensation expense | $ | $ 94,400,000 | ||||||||
Weighted-average period | 2 years 9 months 18 days | ||||||||
2004 Plan [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Option grant prices as percentage of the fair market value of the common stock | 100% | ||||||||
Term to grant nonstatutory stock options and incentive stock options | 10 years | ||||||||
Percentage of options grant to new employees | 25% | ||||||||
Increase in number of authorized shares reserved for issuance | 6,000,000 | ||||||||
Shares available for grant | 9,700,000 | ||||||||
Share based compensation, options exercised, total intrinsic value | $ | $ 46,300,000 | $ 29,300,000 | $ 14,000,000 | ||||||
Intrinsic value of stock options outstanding | $ | $ 261,900,000 | ||||||||
2004 Plan [Member] | New Employee [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Award vesting right | Options granted to new employees generally vest 25% after one year and monthly thereafter over a period of four years | ||||||||
Period from percentage of stock option vested | 1 year | ||||||||
Vesting period | 4 years | ||||||||
Increase in number of authorized shares reserved for issuance | 1,600,000 | ||||||||
2004 Plan [Member] | Existing Employee [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Award vesting right | Options granted to existing employees generally vest monthly over a period of four years | ||||||||
Vesting period | 4 years | ||||||||
ESPP [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Option grant prices as percentage of the fair market value of the common stock | 85% | ||||||||
Number of authorized shares reserved for issuance | 239,887 | ||||||||
Increase in common stock shares reserved for issuance | 500,000 | ||||||||
Issuance of common stock pursuant to ESPP, shares | 98,153 | 108,780 | 134,684 | ||||||
Issuance of common stock pursuant to ESPP, per share | $ / shares | $ 32.89 | $ 16.33 | $ 11.21 | ||||||
Non-employee Stock-Based Compensation [Member] | |||||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||||
Allocated share based compensation expense | $ | $ 100,000 | $ 200,000 | $ 200,000 |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Stock Options Outstanding, Beginning Balance | 9,372,959 | 8,501,949 | 7,759,012 |
Stock Options Outstanding, Granted | 3,424,150 | 2,513,350 | 1,944,562 |
Stock Options Outstanding, Forfeited | (415,675) | (296,146) | (234,054) |
Stock Options Outstanding, Ending Balance | 10,992,403 | 9,372,959 | 8,501,949 |
Stock Options Outstanding, Exercisable | 6,153,725 | ||
Weighted Average Exercise Price per Share, Beginning Balance | $ 13.35 | $ 10.02 | $ 8.59 |
Weighted Average Exercise Price per Share, Granted | 39.79 | 22.43 | 15.59 |
Weighted Average Exercise Price per Share, Exercised | 10.13 | 9.01 | 8.27 |
Weighted Average Exercise Price per Share, Forfeited | 28.94 | 14.56 | 16.06 |
Weighted Average Exercise Price per Share, Ending Balance | 22.13 | $ 13.35 | $ 10.02 |
Weighted Average Exercise Price per Share, Exercisable | $ 13.21 | ||
Weighted Average Remaining Contractual Life | 7 years | ||
Weighted Average Remaining Contractual Life, Exercisable at December 31, 2021 | 5 years 7 months 6 days | ||
Aggregate Intrinsic Value | $ 261.9 | ||
Aggregate Intrinsic Value, Exercisable at December 31, 2021 | $ 200.7 | ||
Common Stock [Member] | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Stock Options Outstanding, Exercised | (1,389,031) | (1,346,194) | (967,571) |
Stockholders' Equity - Summar_2
Stockholders' Equity - Summary of Restricted Stock Unit Activity Including Performance Stock Units (Detail) - Restricted Stock Units (RSUs) Including Performance Stock Units (PSUs) - $ / shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Number of Restricted Stock Units, Beginning Balance | 1,414,827 | 1,116,642 | 839,075 |
Number of Restricted Stock Units, Granted | 780,519 | 1,093,450 | 731,225 |
Number of Restricted Stock Units, Exercised | (707,772) | (606,240) | (435,450) |
Number of Restricted Stock Units, Forfeited | (273,310) | (189,025) | (18,208) |
Number of Restricted Stock Units, Ending Balance | 1,214,264 | 1,414,827 | 1,116,642 |
Weighted Average Award Date Fair Value per Share, Beginning Balance | $ 18.52 | $ 11.88 | $ 7.49 |
Weighted Average Award Date Fair Value per Share, Granted | 37.69 | 21.69 | 14.40 |
Weighted Average Award Date Fair Value per Share, Exercised | 16.72 | 11.13 | 7.72 |
Weighted Average Award Date Fair Value per Share, Forfeited | 26.65 | 21.32 | 10.37 |
Weighted Average Award Date Fair Value per Share, Ending Balance | $ 30.07 | $ 18.52 | $ 11.88 |
Stockholders' Equity - Fair Val
Stockholders' Equity - Fair Value of Share-Based Payments was Estimated on Date of Grant Based on Assumptions (Detail) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Options [Member] | |||
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items] | |||
Risk-free interest rate, minimum | 1.41% | 0.58% | 0.42% |
Risk-free interest rate, maximum | 4.01% | 1.28% | 1.80% |
Volatility, minimum | 66% | 66% | 74% |
Volatility, maximum | 67% | 67% | 75% |
Expected dividend yield | 0% | 0% | 0% |
Minimum [Member] | Options [Member] | |||
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items] | |||
Expected term in years | 6 years 3 months 18 days | 6 years 4 months 24 days | 6 years 6 months |
Maximum [Member] | Options [Member] | |||
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items] | |||
Expected term in years | 6 years 4 months 24 days | 6 years 6 months | 6 years 7 months 6 days |
ESPP [Member] | |||
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items] | |||
Risk-free interest rate, minimum | 1.63% | 0.11% | |
Risk-free interest rate, maximum | 4.65% | 1.80% | |
Risk-free interest rate | 0.05% | ||
Volatility, minimum | 64% | 66% | 74% |
Volatility, maximum | 65% | 67% | 75% |
Expected term in years | 6 months | 6 months | 6 months |
Expected dividend yield | 0% | 0% | 0% |
Stockholders' Equity - Summar_3
Stockholders' Equity - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | |||
Stock-based compensation expense | $ 47,853 | $ 26,832 | $ 17,620 |
Research and Development [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | |||
Stock-based compensation expense | 19,100 | 10,463 | 6,949 |
General and Administrative [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | |||
Stock-based compensation expense | $ 28,753 | $ 16,369 | $ 10,671 |
Stockholders' Equity - Summar_4
Stockholders' Equity - Summary of Outstanding Warrants Issued (Details) - Oxford and Silicon Valley Bank [Member] - New Loan and Security Agreement [Member] - 2019 Term Loan [Member] - $ / shares | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2019 | |
Class of Warrant or Right [Line Items] | ||||
Warrants Exercised | 34,765 | 139,297 | ||
Warrants Outstanding | 12,957 | 47,722 | 47,722 | 165,424 |
January 2020 [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Expiration Date | 2030-01 | |||
Exercise Price | $ 10.42 | |||
Warrants Exercised | 8,638 | 0 | ||
Warrants Outstanding | 12,957 | 21,595 | 21,595 | 0 |
May 2019 [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Expiration Date | 2029-05 | |||
Exercise Price | $ 9.76 | |||
Warrants Exercised | 9,226 | 13,839 | ||
Warrants Outstanding | 0 | 9,226 | 9,226 | 23,065 |
August 2018 [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Expiration Date | 2028-08 | |||
Exercise Price | $ 7.10 | |||
Warrants Exercised | 16,901 | 25,352 | ||
Warrants Outstanding | 0 | 16,901 | 16,901 | 42,253 |
February 2016 [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Expiration Date | 2026-02 | |||
Exercise Price | $ 6.59 | |||
Warrants Exercised | 51,214 | |||
Warrants Outstanding | 0 | 0 | 51,214 | |
October 2015 [Member] | ||||
Class of Warrant or Right [Line Items] | ||||
Expiration Date | 2025-10 | |||
Exercise Price | $ 6.90 | |||
Warrants Exercised | 48,892 | |||
Warrants Outstanding | 0 | 0 | 48,892 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||||||
Jan. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 01, 2022 | Aug. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2019 | |
Lessee Lease Description [Line Items] | ||||||||
Operating lease right-of-use assets | $ 82,737 | $ 73,138 | ||||||
Operating lease, short-term lease liability | 12,829 | 14,863 | ||||||
Operating lease, long-term lease liability | 126,895 | 112,229 | ||||||
Impairment of right-of-use assets | $ 0 | 2,844 | $ 0 | |||||
Finance lease, contractual lease term | 3 years | |||||||
Rent expense for operating and finance leases | $ 21,600 | 23,100 | 5,700 | |||||
Lease Agreement | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, cash paid included in net cash used in operating activities | $ 24,100 | $ 6,100 | ||||||
Financial lease estimated life | 5 years | |||||||
Finance Lease, Right-of-Use Asset | $ 2,400 | |||||||
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] | Property and equipment, net | |||||||
Short term finance lease liability | $ 1,000 | |||||||
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Other current liabilities | |||||||
Long term finance lease liability | $ 1,000 | |||||||
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other non-current liabilities | |||||||
Finance lease, weighted average remaining lease term | 4 years | |||||||
Finance lease, weighted average discount rate | 9.47% | |||||||
Finance lease payments | $ 900 | |||||||
Current Lease [Member] | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, lease expiration date | Jun. 30, 2022 | |||||||
Oyster Point Lease [Member] | California [Member] | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, lease expiration date | Oct. 31, 2033 | |||||||
Operating lease, commencement date | Mar. 31, 2021 | |||||||
Operating lease right-of-use assets | $ 77,900 | |||||||
Operating lease, short-term lease liability | 3,700 | |||||||
Operating lease, long-term lease liability | 85,300 | |||||||
Operating lease, tenant improvement reimbursements | $ 11,100 | |||||||
Operating lease, weighted average remaining lease term | 10 years 9 months 18 days | |||||||
Operating lease, weighted average discount rate | 8.70% | |||||||
Operating lease, security deposit liability | $ 5,100 | $ 5,100 | ||||||
Operating lease agreement allowances for tenant improvements | $ 43,600 | |||||||
Operating lease undiscounted lease payments | $ 220,400 | |||||||
Operating lease commenced, term description | we have two consecutive five-year options to extend the lease. | |||||||
Radnor Lease [Member] | Pennsylvania [Member] | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, commencement date | Sep. 01, 2022 | |||||||
Operating lease right-of-use assets | $ 3,400 | |||||||
Operating lease, short-term lease liability | 400 | |||||||
Operating lease, long-term lease liability | $ 1,900 | |||||||
Operating lease, tenant improvement reimbursements | $ 300 | |||||||
Operating lease, weighted average remaining lease term | 4 years 7 months 6 days | |||||||
Operating lease, weighted average discount rate | 8.30% | |||||||
Operating lease agreement allowances for tenant improvements | $ 1,200 | |||||||
Operating lease undiscounted lease payments | $ 2,800 | |||||||
Operating lease commenced, term description | We will then continue to lease the premises with the landlord through July 31, 2027 with one five-year option to extend the lease. | |||||||
Right-of-use asset, prepayment | $ 1,100 | |||||||
Radnor Lease [Member] | Pennsylvania [Member] | Sub Landlord [Member] | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, lease expiration date | May 31, 2024 |
Commitments and Contingencies_2
Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-cancellable Lease (Detail) $ in Thousands | Dec. 31, 2022 USD ($) |
Leases [Abstract] | |
2023 | $ 13,465 |
2024 | 18,738 |
2025 | 19,563 |
2026 | 20,180 |
2027 | 20,514 |
Thereafter | 130,719 |
Total future minimum lease payments | 223,179 |
Less: Imputed interest | (83,455) |
Total lease liability | 139,724 |
2023 | 990 |
2024 | 990 |
2025 | 204 |
2026 | 0 |
2027 | 0 |
Thereafter | 0 |
Total future minimum lease payments | 2,184 |
Less: Imputed interest | (183) |
Total lease liability | $ 2,001 |
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] | us-gaap:OtherLiabilities |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Contingency [Line Items] | |||
Provision for income tax | $ 0 | $ 0 | $ 0 |
Increase (decrease) in valuation allowance | $ 116,500,000 | 52,600,000 | |
Research and development credits and orphan drug credits, federal carryforwards will expire | 2022 | ||
Unrecognized tax benefits | $ 17,700,000 | $ 10,300,000 | $ 9,600,000 |
California Income Tax Purposes [Member] | |||
Income Tax Contingency [Line Items] | |||
Credit carryforwards for federal and state | 21,000,000 | ||
Federal Tax [Member] | |||
Income Tax Contingency [Line Items] | |||
Net operating loss carryforwards | $ 834,400,000 | ||
Net operating loss carryforwards expiration | 2022 | ||
Credit carryforwards for federal and state | $ 99,400,000 | ||
Federal and State Tax [Member] | |||
Income Tax Contingency [Line Items] | |||
Net operating loss carryforwards | $ 367,100,000 | ||
Net operating loss carryforwards expiration | 2028 |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Effective Tax Rate (Detail) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |||
Tax at federal statutory tax rate | 21% | 21% | 21% |
State tax, net of federal benefits | 1% | 0% | 1% |
Change in state effected rates | 0% | (1.00%) | (2.00%) |
Tax credits, net | 4% | 3% | 3% |
Change in valuation allowance | (26.00%) | (24.00%) | (23.00%) |
Stock-based compensation | 2% | 2% | 1% |
Other | (2.00%) | (1.00%) | (1.00%) |
Total | 0% | 0% | 0% |
Income Taxes - Summary of Defer
Income Taxes - Summary of Deferred Tax Assets, Net (Detail) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Deferred tax assets: | ||
Net operating loss carryforwards | $ 202,459 | $ 181,977 |
Tax credits | 98,292 | 77,366 |
Liability related to sale of future royalties | 68,366 | 38,302 |
Reserves and accruals | 23,950 | 15,409 |
Capitalized R&D | 48,047 | 1,115 |
Long-term lease liability | 28,901 | 26,223 |
Deferred revenue | 0 | 18,608 |
Total noncurrent deferred tax assets | 470,015 | 359,000 |
Deferred tax liabilities: | ||
Depreciation and amortization | (7,909) | (7,664) |
Operating lease right-of-use assets | (18,192) | (15,643) |
Convertible notes | 0 | (8,296) |
Total noncurrent deferred tax liabilities | (26,101) | (31,603) |
Less: Valuation allowance | (443,914) | (327,397) |
Net deferred tax assets | $ 0 | $ 0 |
Income Taxes - Schedule of Acti
Income Taxes - Schedule of Activity Related to our Gross Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |||
Balance at the beginning of the year | $ 11,295 | $ 10,522 | $ 9,922 |
Increase related to prior year tax positions | 4,438 | ||
Decrease related to prior year tax positions | (1,804) | (29) | (3) |
Increase related to current year tax positions | 4,426 | 802 | 603 |
Balance at the end of the year | $ 18,355 | $ 11,295 | $ 10,522 |